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Summary 
Accurate stratification of tumors is an imperative step for adequate cancer management. In 
addition to staging, morphological subtyping allows stratifying patients into additional 
prognostic groups. In this thesis, we have used an image-based computational method on pan-
cytokeratin immunohistochemical (IHC) stainings to quantify clinically relevant morphologic 
parameters.   
We conducted our analysis on surgically resected lung squamous cell carcinomas (LSCC) and 
identified tumor fragmentation (TF), as a measure of tumor invasiveness. We showed on two 
independent clinical cohorts from tissue microarrays (TMA) and whole sections (WS) that this 
novel parameter was associated with poor prognosis and increased risk of blood vessel 
infiltration. The poor prognostic value of increasing TF was further confirmed in a third cohort 
from the cancer genome atlas (TCGA) using a similar human-based score on haematoxylin-
eosin (H&E) histochemical stainings. The integration of mRNAseq data from TCGA, and LC-
MS/MS proteomics from WS, revealed an up-regulation of extracellular matrix remodeling and 
focal adhesion processes in tumors with high TF, supporting their increased invasive potential. 
The proposed histologic parameter is an independent unfavorable prognostic marker that 
could be envisaged as new grading parameter for LSCC. 
We extended our analysis on neoadjuvant chemotherapy treated LSCC in order to characterize 
the histopathologic response to treatment using quantitative morphologic parameters. In this 
setting, chemotherapy is given before surgery thus potentially reducing the tumor burden 
before tumor resection. For this analysis, a cohort of chemo-naïve patients was used for 
comparison. After neoadjuvant chemotherapy, tumor area (Tumorarea), the percentage of 
tumor cells (Tumor%) as well as the amount (TF) and size of the largest residual fragment 
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(Sizemax) were significantly reduced compared to chemo-naïve LSCC. Positron Emission 
Tomography / Computed Tomography (PET/CT) measurements were integrated for 
subsequent correlation analysis against quantitative morphometric parameters. An initial study 
was conducted to assess which PET metrics correlated best with histopathologic tumor 
regression (TRG) scored, using a classic visual scoring system for non-small cell lung carcinomas. 
Our analysis showed that background adaptive PET volume metrics of the metabolic tumor 
volume (BSV) and total lesion glycolysis (BSL) correlated better with histopathological TRG than 
methods using a fixed threshold (42%) of the maximum standard uptake value SUVmax. 
Following on these findings, we evaluated and found that tumorarea was the morphologic 
parameter best correlating with SUVmax, BSL and BSV post chemotherapy whereas PET metric 
before neaoadjuvant therapy were not associated to any morphologic parameter. 
Survival analysis of the morphologic parameters showed that Tumor%, Tumorarea and Sizemax 
were able to stratify patients into risk categories based on a 3-years overall survival cutoff, 
whereas TF was the only significant parameter for chemo-naïve LSCC. Quantitative and 
automatic measurements of the remaining tumor burden could therefore provide the basis of 
an objective TRG system.  
In this doctoral thesis, we highlighted the relevance of using image-based computational 
methods to supervise pathologists for tumor classification, particularly for lung squamous cell 
carcinoma. The proposed approach is not restricted to this particular subtype, and is potentially 
applicable to score morphologic and eventually prognostic parameters for other carcinomas.  
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Zusammenfassung  
Eine angemessene Stratifizierung von Tumoren ist unerlässlich für eine bestmögliche 
Krebsbehandlung. Neben der Bestimmung des Tumorstadiums verhilft eine morphologische 
Subtypisierung zur Unterteilung in zusätzliche prognostische Subgruppen. 
In der vorliegenden Arbeit wurde eine bildbasierte Berechnungsmethode für die 
Quantifizierung von klinisch relevanten morphologischen Merkmalen anhand von pan-
Zytokeratin-immunhistochemischen Färbungen (IHC) eingesetzt.  Durch Analysen von operativ 
entfernten Plattenepithelkarzinomen der Lunge (LSCC), wurden Tumorfragmentierungen (TF) 
als Maß für die Invasivität von Tumoren ermittelt.   
Zwei unabhängige klinische Studien, von denen tissue microarrays (TMAs) und Gewebeschnitte 
(WS) untersucht wurden, zeigten, dass dieser neue Parameter mit einer schlechteren Prognose 
und einem erhöhten Blutgefässinfiltrationsrisiko korreliert. Die Aussagekraft einer hohen TF als 
ungünstiger prognostischer Marker wurde an einer dritten Kohorte aus der TCGA-Datenbank 
bestätigt. Hierbei wurde eine ähnliche subjektive Auswertung (Scoring) für HE-Färbungen 
eingesetzt. mRNAseq-Daten aus der TCGA-Datenbank und LC-MS/MS Proteom-Daten aus den 
WS zeigten verstärktes «Remodelling» der extrazellulären Matrix und der fokalen Adhäsionen 
in Tumoren mit hoher TF, was die erhöhte Invasivität unterstützt. Der hier beschriebene 
histologische Parameter ist ein unabhängiger prognostischer Marker, der als neuer Faktor für 
die Stadiums Bestimmung von LSCC herangezogen werden könnte. 
Um das histopathologische Ansprechen mittels quantitativer morphologischer Parameter zu 
charakterisieren, wurde die Studie mit Patienten unter Einfluss von neoadjuvanter 
Chemotherapie erweitert. Um eine potentielle Tumorlast vor der Resektion zu reduzieren, 
wurde den Patienten vor der Operation Chemotherapie verabreicht. Bei dieser Analyse wurden 
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chemo-naive Patienten als Kontrollgruppe herangezogen. Nach neoadjuvanter Chemotherapie 
waren sowohl das Tumorareal und der Prozentanteil an Tumorzellen, als auch die Menge und 
Grösse der grössten Restfragmente signifikant reduziert im Vergleich zu den chemo-naiven 
LSCCs. Die Korrelation von PET/CT Messungen mit quantitativen morphometrischen 
Parametern wurde in der nachfolgenden Analyse untersucht. Es wurde eine Studie, die auf 
einer klassischen visuellen Auswertung für NSCLC basiert, durchgeführt. Hierbei sollte 
untersucht werden, welche PET-Metrik am besten mit der ausgewerteten histopathologischen 
Tumorregression (TRG) korreliert. Unsere Analyse zeigt, dass die adaptive PET-
Hintergrundsvolumenmetrik des metabolischen Tumorvolumens (BSV) und der totalen 
Läsionsglykolyse (BSL) besser mit der histopathologischen TRG korreliert als Methoden, die 
einen festen Prozentsatz (42%) von der maximalen Standardaufnahme SUVmax verwenden. Im 
Anschluss zeigte sich, dass man anhand des Tumoranteils (%), der Tumorarea und der 
maximalen Grösse, die Patienten in drei Risikokategorien, hinsichtlich deren 3-Jahre 
Gesamtüberleben, unterteilen konnte. Dagegen war die TF der einzige signifikante Parameter 
bei den chemo-naiven LSCC. Quantitative automatische Messungen der Resttumorlast könnte 
die Basis für eine objektive TRG bieten. 
In der vorliegenden Dissertation wurde die Relevanz von bildbasierten Berechnungsmethoden 
unterstrichen, die den Pathologen bei der Tumorklassifikation unterstützen können, 
insbesondere bei LSCC. Der dargestellte Ansatz ist nicht auf einen spezifischen Subtyp begrenzt 
und kann potentiell für die Auswertung von morphologischen und letztendlich prognostischen 
Parametern anderer Karzinome angewandt werden.  
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Introduction 
Lung cancer epidemiology 
Lung cancer is the most frequent cancer worldwide with more than 1.8 million newly diagnosed 
cases in 2012, as indicated in the latest World Cancer Report 2014. It is also the leading cause 
of cancer deaths with an estimate of 1.6 million deaths, followed by liver and stomach cancer 
(1). The disease is largely attributed to tobacco smoking habits with estimated 90% to 95% of 
European and North American cases for men and 74% to 85% for women (2). In addition, 
smokers have a 10 to 20-fold increased risk of lung cancer as opposed to never smokers (3). 
Additional risk factors include radon exposure, asbestos, metals, silica dust among others in 
addition to radiation such as X-rays and gamma rays (4-9). In Switzerland, lung cancer is also 
the most frequent cause of cancer death, with approximately 3000 people dying each year (10). 
This accounts for 22% of all cancer deaths among men and 14.9% among women (Figure 1). 
 
Figure 1: New cases and deaths by cancer site, 2008-2012. Arnt et al. Swiss Cancer Report 2015. Bar plots showing 
the number of new cases and deaths per cancer stratified by sex. 
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Lung cancer types  
Lung carcinoma is a malignancy of the lung and respiratory tracts and comprises two main 
groups: small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). NSCLC is 
the most frequent type and accounts for 85% of all lung cancers. The two major subtypes of 
NSCLC are adenocarcinoma (ADC) and lung squamous carcinoma (LSCC) - the latter 
representing 25-30% of all lung cancer in Europe (11). Lung cancer arises in different anatomical 
compartments of the lung, thus giving rise to distinct major histological types (Figure 2) (12). 
NSCLC is an epithelial malignancy assumed to originate from alveolar or bronchial epithelial 
cells, whereas SCLC is thought to arise from cells showing neuro-endocrine features and 
eventual stemness traits (13, 14). In general, LSCC and SCLC are preferentially located in the 
central compartments of the lung, which include large branching bronchi and bronchioles. ADC 
is considered to arise from the peripheral compartments of the lung, where terminal 
bronchioles are more represented.  
Tumor imaging and clinical staging 
Initial staging of lung cancer generally starts with a radiographic imaging of the chest in order 
to perform a pre-assessment of the tumor extent of the disease. The clinical TNM staging 
(primary tumor, lymph nodes and distant metastasis) is nowadays performed by computed 
tomography (CT) in combination with positron emission tomography (PET), since it is a non-
invasive approach to measure tumor size, mediastinal node enlargement, and potential 
metastases. (15, 16). PET has a poorer resolution than CT and is not adequate to measure the 
local extent of the tumor. However, it is a readout for the tumor metabolic activity, which is 
usually measured using the standardized uptake value (SUV). This method is useful to 
differentiate malignant lesions, which are hyper-metabolic, from benign lesions (17). In 
addition, PET-CT scans may allow reducing the number of futile thoracotomies but does not 
 
 
10  
seem to affect patient’s survival (18). However, PET-CT alone is not sensitive and specific 
enough to guide disease management which would require tissue biopsies before deciding 
further treatment options (19). 
 
Figure 2: Lung compartments and cell types. Sun S. et al. Nat Rev Cancer 2007. 
  
 
 
11  
Pathologic staging 
The standard of care for patients diagnosed with NSCLC depends on the extent of the disease. 
TNM staging is the main classification system and allows stratifying patients into prognostic 
groups. In this model, the anatomical extent of the cancer is assessed by examining the primary 
tumor (T), lymph nodes (N) and the presence of distant metastasis (M) (Figure 3).  
 
Figure 3: TNM classification of lung cancer. Adapted from https://cancerstaging.org/references-
tools/quickreferences/Pages/default.aspx 
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Staging is primordial for adequate disease management since different treatment modalities 
are proposed according to the tumor stage. For early stages (I and II), surgical resection is the 
main treatment option and can in addition be followed by cisplatin-based adjuvant 
chemotherapy, notably for stages II-III NSCLC. For locally advanced NSCLC (stage III) or 
metastatic stage IV, disease management is individualized and require multimodal treatments 
(20). Neoadjuvant or induction chemotherapy can be performed in order to reduce the tumor 
burden before resection but this is so far not a standard treatment option.  
Histopathologic subtyping 
NSCLC is a heterogeneous disease including several histological subtypes. ADC and SCC are the 
two main histologic subtypes in addition to adeno-squamous or large cell neuroendocrine 
tumors. Histologically, ADC is characterized by the formation of glands often secreting mucin 
whereas SCC is recognized by the presence of keratin and/or intercellular desmosomes. Large 
cell carcinoma has no differentiating features (null phenotype) and is thus a poorly 
differentiated NSCLC. A panel of immunohistochemistry (IHC) stains is used to complete the 
diagnostic in case of doubts concerning the histological subtype. In practice, p40 and p63 serve 
as squamous markers and are therefore used to distinguish SCC whereas thyroid transcription 
factor (TTF-1) and mucin are the main markers for ADC (21). IHC cytokeratin cocktails such as 
AE1/AE3, which detects CK1-8, 10, 14-16 and 19, are also frequently used to rule out or confirm 
the epithelial nature of the cancer. 
In addition, histologic subtyping is an important factor for treatment decisions. In clinical 
practice, different therapies are proposed to non-squamous NSCLC due to higher toxicity or 
reduced efficacy in SCC. As an example, the use of Pemetrexed, a chemotherapy drug and 
Bevacizumab, an antiangiogenic – anti vascular endothelial growth factor (VEGF) - antibody, 
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are restricted to non-squamous NSCLC (22-24). In addition, several recurrent genetic 
alterations are almost constantly constrained to a particular histology, e.g. EGFR mutations in 
adenocarcinoma. 
Molecular subtyping  
Molecular subtyping is a primordial component for personalized treatment. In addition to 
histologic subtyping, molecular testing is performed to detect the presence of specific 
mutations in order to tailor more personalized treatments (25). In fact, in NSCLC, the 
identification of recurrent genetic alterations in multiple oncogenes have led to therapeutic 
strategies notably with the approval of drugs specific to tumors harboring mutations in the 
epidermal growth factor receptor (EGFR) or rearrangements in the anaplastic lymphoma kinase 
(ALK) and the ROS1 gene. These genetic alterations are frequent in adenocarcinoma but are 
only rarely found in lung SCLC (Figure 4). EGFR mutations are observed in 10-35% of NSCLC but 
almost exclusively seen in adenocarcinoma. The detection of EGFR mutations is recommended 
being done by polymerase chain reaction (PCR). Tumors with specific EGFR mutations occurring 
within EGFR exons 18–21, located in the EGFR kinase domain, have an increased sensitivity to 
Receptor Tyrosine Kinase Inhibitors (RTKIs), such as Gefinitib (26, 27) and Erlotinib (28).  ALK 
rearrangements lead in majority to the fusion of ALK gene with portions of the echinoderm 
microtubule-associated protein-like 4 (EML4) gene. They occur in 3-7% of NSCLC - 
predominantly in adenocarcinomas with acinar features- and are more often associated with 
young and light/non-smokers (29-34).  
ROS1 rearrangements occur in 1% of NSCLC and similarly to ALK translocations, can be detected 
using immunohistochemistry (IHC), fluorescence in-situ testing (FISH) or by next-generation 
sequencing (NGS). NSCLC with ALK and ROS1 rearrangements can be currently be treated with 
Crizotinib, a potent dual ALK/MET tyrosine kinase inhibitor. Other potentially targetable genetic 
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alterations have been identified in NSCLC but have up to day no drugs approved for this type 
of cancer or are still under development. This includes mutations in KRAS (15-25%), PTEN (4-
8%), BRAF (1-3%), HER2 (2-4%), DDR2 (~4%), MET (2-4%), PIK3CA (1-3%), AKT1 (1%), MEK1 
(1%), NRAS (1%) as well as RET rearrangements (1%) and FGFR1 amplifications (20%) (35).  
 
Figure 4: Evolution of lung cancer histology over time, adapted from Reck M. et al. Lancet 2013 
 
Despite the presented efficacy of targeted therapies, the vast majority of patients experience 
cancer relapse due to acquired resistance of the tumor, which can be caused by gene 
alterations within the drug target, or activations of alternative oncogenic pathways (36, 37). An 
example of acquired resistance mechanism is the interference of the inhibitor with its EGFR 
binding domain, which is caused by the EGFR T790M mutation (38-40). This led to the 
development of inhibitors targeting EGFR T790M mutation such as Osimertinib, an FDA 
approved drug for metastatic NSCLC baring this specific mutation.  
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Alternatively, cancer immunotherapy is a promising strategy whose aim is to tackle immune 
evasion, a hallmark of cancer (41). Immunologic checkpoint blockade - using antibodies 
targeting the programmed cell death protein 1 pathway (PD-1/PD-L1) - is a promising treatment 
strategy for NSCLC. PD-1 and PD-L1/PD-L2 are immune checkpoint proteins acting as co-
inhibitory factors. While PD-1 is expressed in activated T cells whereas, PD-L1 and PD-L2 are 
commonly expressed on the surface of macrophages and dendritic cells. However, tumor cells 
may also express PD-L1 leading to the inhibition of T-cell response (42, 43). There are numerous 
ongoing phase III clinical trials based on immune checkpoints blockade using antibodies against 
PD1 (Nivolumab, Pembrolizumab) and PD-L1 (Atezolizumab, Durvalumab). Several clinical trials 
have shown the efficacy of anti PD-1 immunotherapy and most recently, Pembrolizumab 
combined with carboplatin and Pemetrexed chemotherapy has been approved by the Food and 
Drugs Administration (FDA) as first line treatment of non-squamous NSCLC (44-46). 
Morphologic subtyping for NSCLC grading 
In addition to staging, tumor grading aims at further stratifying tumors into prognostic groups, 
according to morphologic criteria. Despite ongoing efforts in this field, there are currently no 
established grading criteria for NSCLC (21). Nevertheless, as proposed by the International 
Association for the Study of Lung Cancer (IASLC)/the American Thoracic Society (ATS)/the 
European Respiratory Society (ERS), adenocarcinoma can present five distinct morphologic 
subtypes: lepidic, acinar, papillary, micropapillary and solid (figure 5) (47). The determination 
of the predominant pattern has been shown to be prognostic and has been suggested as 
grading parameter (48-52).   
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Figure 5: Hematoxylin and Eosin (H&E) stained histologic sections magnified 25x (square 80x) showing the main 
morphologic subtypes for adenocarcinoma. A) lepidic, B) papillary, C) acinar, D) solid, E) micro-papillary patterns. 
Unpublished data. 
 
The presence of keratinization is the main feature of lung SCC and defines the degree of 
differentiation. Prominent keratinization is associated with well-differentiated SCC while poorly 
differentiated tumors have only focal or non-apparent keratinization. Basaloid SCC is a form of 
poorly differentiated squamous cell carcinoma, morphologically described by smaller cells 
forming lobular structures with peripheral palisading (figure 6).  However, the prognostic value 
of this parameter remains unclear. Other prognostic parameters such as tumor budding, single 
cell invasion, stromal thickness have been suggested as grading parameters but are currently 
not in use in routine pathology (53-56).  
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Figure 6: H&E stained histologic sections magnified 25x (square 80x) showing the main morphologic subtypes of 
lung squamous cell carcinoma. A) poorly differentiated/non-keratinizing, B) well differentiated/keratinizing, C) 
basaloid. Unpublished data.   
 
Digital pathology as a tool for quantitative tumor morphologic analysis 
Digital pathology is an emerging field aiming at improving tissue diagnostic by computerized 
approaches. With the development of high-resolution scanners allowing to scan whole tissue 
samples at 40x magnification and higher, it has been shown that digitalization of tumor tissue 
does not affect the diagnostic power in pathology (57). The most common applications include 
chromogenic immunohistochemistry (IHC) or immunofluorescence (IF) staining quantification 
as well as morphologic features extraction and quantification (58).  
In the setting of routine pathology, Hematoxylin and Eosin (H&E) is the standard histochemical 
staining to evaluate histological morphology. Protein expression is routinely evaluated by IHC 
and chromogenic IHC is preferred over IF because the stained section can be preserved over 
decades and evaluated by bright field microscopy. Automated IHC analysis can be used for 
biomarker measurement (59), and has proven to yield to similar results from expert 
pathologists (60). While the human eye is highly efficient in recognizing patterns, the 
quantification of morphologic features is more challenging. In their routine, pathologists assess 
the histologic grade of the tumor in order to inform about the tumor aggressiveness, which is 
directly related to patient’s prognosis. However, they are limited to a semi-quantitative scheme 
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to grade the disease. Computerized histological image analysis has demonstrated the ability to 
stratify tumors into prognostic groups using machine-learning algorithms on morphologic 
parameters extracted from tumor and surrounding cells (61-63). It has also shown to be 
efficient in detecting tumor metastases on whole histologic slides (64). Due to the tremendous 
image availability and because H&E discriminates nuclear and subcellular features, the vast 
majority of studies rely on this staining. While these methods focus on subcellular features, 
accurate quantification of higher-level structural features of the tumor epithelia and 
surrounding stroma is more challenging. A straightforward color-based segmentation approach 
can be achieved using chromogenic IHC, with antibodies specific to epithelial structures (65, 
66). Furthermore, it has been shown that cytokeratin staining improves the pathologic 
evaluation of spread tumor buds (67, 68). As depicted above, current efforts lay on the 
development of diagnostic companions for pathologists in order to improve efficiency, 
accuracy and consistency in histopathology evaluations (69).  
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Aims 
The aim of this doctoral study was to develop a computerized approach to support the 
pathologic evaluation of tumor tissue, in particular lung squamous cell carcinoma. An IHC-based 
method - using AE1/AE3 antibodies - was used to stain specifically tumor epithelia, to extract 
features related to the tumor microarchitecture.  
In Chapter 2, the main objective was to quantify histologic prognostic markers, which are able 
to stratify patients into risk groups, based on tumor morphology. For this purpose, we 
addressed the prognostic relevance of tumor fragmentation (TF), a hypothetical histologic 
marker of increased invasiveness, using two cohorts of LSCC patients. Additionally, we included 
an external cohort of LSCC patients in order to test the prognostic value of a human-based TF 
scoring system using standard H&E sections. Finally, molecular data was integrated to our 
morphometric analysis was in order to characterize the biological processes associated to high 
TF.  
In Chapter 3, we applied a similar morphometric analysis to characterize morphological 
changes after neoadjuvant chemotherapy. The objective of this project was to provide a 
quantitative tumor regression model, which could be used to refine current pathologic 
response after chemotherapy. For this purpose, a cohort of neoadjuvant chemotherapy treated 
LSCC cohort was compared to a chemo-naïve cohort. Four morphologic parameters related to 
the size and extension of the remaining tumor burden were evaluated. The performances of 
human-based scores for tumor regression were compared with the generated morphometric 
data. Additionally, we integrated FDG PET/CT parameters in order to correlate the tumor 
metabolic activity - before and after chemotherapy - with quantitative histologic features.  
 
 
20  
In Chapter 4 an initial study, evaluating the performances of several FDG PET/CT measurements 
in discriminating histopathologic response for NSCLC, is presented. The aim of this study was 
to identify which metabolic values - among the most common measurements – correlated best 
with pathologic tumor regression, assessed by conventional light microscopy.  
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Abstract 
Accurate stratification of tumors is an imperative step for adequate cancer management. In 
addition to staging, morphological subtyping allows stratifying patients into additional 
prognostic groups. In this study, we used an image-based computational method on pan-
cytokeratin immunohistochemical (IHC) stainings to quantify tumor fragmentation (TF), a 
measure of tumor invasiveness of lung squamous cell carcinoma (LSCC). We showed on two 
independent clinical cohorts from tissue microarrays (TMA: n=208 patients) and whole sections 
(WS: n=99 patients) that this novel parameter was associated with poor prognosis and 
increased risk of blood vessel infiltration. The poor prognostic value of increasing TF was further 
confirmed in a third cohort from the cancer genome atlas (TCGA: n=335 patients) using a similar 
human-based score on haematoxylin-eosin (H&E) histochemical stainings. The integration of 
mRNAseq data from TCGA, and LC-MS/MS proteomics from WS, revealed an up-regulation of 
extracellular matrix remodeling and focal adhesion processes in tumors with high TF, 
supporting their increased invasive potential. The proposed histologic parameter is an 
independent unfavorable prognostic marker that could be envisaged as new grading parameter 
for LSCC.  
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Introduction 
Lung squamous cell carcinoma (LSCC) is the second most frequent histological subtype of non-
small cell lung carcinoma (NSCLC), accounting for 25-30% of all lung cancers in Europe (11). 
According to the 2015 WHO classification, LSCCs are further separated into keratinizing and 
non-keratinizing subtypes. However, the prognostic relevance of this subtyping remains 
unclear (53, 54). Stratification of lung cancers is an imperative step for adequate disease 
management and is primarily achieved by TNM staging (primary tumor extent, lymph nodes 
status and distant metastases). In addition, tumor grading based on morphological parameters 
such as overall architecture or cell and nuclear pleomorphism also allows stratifying patients 
into prognostic groups. However, there is still no well-established grading system for LSCC (21).  
Tumor invasion is supported by de novo formation of desmoplastic stroma, which provides not 
only physical support to cancer cells but also favors tumor expansion and invasion as a net 
effect of tumor-stroma inter-talk (41). LSCC invasion is histologically characterized by tumor 
clusters of variable sizes surrounded by such specialized stroma. This is reflected by an apparent 
fragmentation of both central and peripheral portions of the tumor mass. The quantification of 
such tumor fragments on whole histological sections may be used as a metric for tumor 
aggressiveness which could serve as a novel grading parameter to stratify LSCC into prognostic 
groups. 
In this study, we performed an image-based computational analysis for unbiased tumor 
fragmentation (TF) quantification and applied extended the method with a human-based 
scoring system relevant for pathologists. Additionally, we integrated tumor histology with 
molecular data to evaluate the biological processes associated to this morphological feature. A 
retrospective study on three independent clinical cohorts was performed to assess the 
potential prognostic relevance of TF as novel grading parameter for LSCC. 
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Materials and Methods  
Patient cohorts 
In this retrospective study, consecutive patients with surgical resection of their primary lung 
SCC at the University Hospital Zurich were selected. Squamous cell differentiation was reviewed 
on haematoxylin-eosin (H&E) and alcian blue-periodic acid schiff (AB-PAS) stains. Differential 
diagnosis of non-keratinizing SCC versus solid adeno-, null-phenotype or neuroendocrine large 
cell carcinoma was performed by respective IHC using TTF1, p40, p63, CK7 and synaptophysin 
antibodies. Cases with mixed or unclear histology were excluded. Patients with synchronic or 
metachronic second primary tumor in particular head and neck SCC, with neo-adjuvant chemo-
/radiotherapy or with overall survival (OS) < 1 month post-surgery were also excluded. The TMA 
cohort consisted of 233 lung SCC patients between January 1993 and December 2002, as 
described (70). Patients were further excluded if the quality of the pan-cytokeratin IHC was 
insufficient for automatic image analysis on both cores, e.g. due to presence of non-cancerous 
tissue, more than 80% stroma or major cutting artefacts. In total 208 patients met inclusion 
criteria. Adjuvant treatment was administered to 75 (36%) patients from which 62 (82%) 
received radiotherapy, 8 (11%) chemotherapy and 5 (7%) both. The WS cohort consisted of 
non-redundant 167 patients between January 2003 and February 2010 having complete clinical 
data. After revision for exclusion criteria, 99 patients were included. Adjuvant therapy was 
administered to 30 (30%) of the patients from which 6 (20%) received radiotherapy, 20 (67%) 
chemotherapy and 4 (13%) both. TCGA clinical data was downloaded from cBioPortal for 
Cancer Genomics, Memorian Sloan Kettering Cancer Center (71) for 504 lung SCC patients. 
After exclusion due to OS<1 month, neo-adjuvant chemotherapy or insufficient image quality, 
335 patients remained. Thirty-one (9%) patients had a documented adjuvant therapy whereby 
3 (10%) received radiotherapy, 21 (68%) targeted therapy and 7 (22%) both. Our study was 
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approved by the Ethical Commission of the Canton of Zurich under reference number KEK ZH-
Nr. 29-2009/14.  
Tissue microarray construction and immunohistochemistry 
For the TMA cohort, two representative paraffin blocks with tumor were selected. One tissue 
core of 600µm diameter was taken from each tissue block and transferred into a recipient 
block. For the whole sections cohort, two blocks representing best the overall tumor 
morphology were selected and 2µm thick sections were cut from each block. 
Immunohistochemistry (IHC) was performed on an automated platform (Ventana Medical 
Systems, Tucson, AZ, USA) using mouse monoclonal anti-human cytokeratin AE1/AE3 (M3515, 
DAKO, dilution 1:50), rabbit polyclonal Periostin (Abcam, 1:1000) and mouse monoclonal 
Versican (2B1, Seikagaku, 1:500). Detection was completed with a respective secondary 
antibody and the OptiView DAB kit (Ventana Medical Systems).  
Image acquisition 
Immunohistochemically stained sections were scanned with a high-resolution whole slide 
scanner (Nanozoomer Digital Pathology, Hamamatsu, Japan) using a 40x objective with spatial 
resolution of 0.23µm/pixel. TMA and whole sections images were analyzed with a spatial 
resolution of 1.84µm/pixel and 9.2µm/pixel, respectively. Whole sections were further 
annotated by a surgical pathologist (A.S.) in order to select tumor tissue. The surrounding non-
tumor lung tissue was excluded from the analysis. A formalin-fixed cylindrical tissue sample of 
1 cm diameter from a pT3 lung SCC was imaged by X-ray microtomography at the beamline for 
tomographic microscopy and coherent radiology experiments (TOMCAT), Paul Scherrer 
Institute (PSI, Würenlingen, Switzerland). Sample was scanned using a microscope equipped 
with a PCO-Edge camera mounted with a 10x objective for a spatial resolution of 0.65µm /pixel 
using propagation-based X-ray phase contrast CT, as described (72).  
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Image processing 
Automatic morphometric analysis was performed using FIJI (73). Color-based segmentation 
allowed separating the tumor tissue (brown) from its surrounding stroma (blue/grey). Color 
threshold values were previously validated by the pathologist. A similar approach for tumor 
segmentation by cytokeratin stained sections has been described for colon carcinoma (65). The 
segmentation algorithm included mean shift and median filtering, color thresholding using the 
L*a*b color space and particle size filtering with a minimum size threshold of 100µm2, 
considered as noise. The resulting segmentation masks were used for automated scoring of 
tumor fragmentation.  
Tumor fragmentation scoring 
Tumor fragments refer to tumor clusters completely separated from each other on a two-
dimensional plane by intervening desmoplastic stroma. Tumor fragmentation was 
automatically scored on the pan-CK stainings of both TMA and WS by counting the total number 
of disconnected particles larger than 800µm2 (circa ≥ 5 cells) for each segmentation mask. TF 
scores were summed up over two images when available or duplicated for cases with single 
images. In addition, 88/99 WS patients were also represented on a secondary TMA from which 
77 had sufficient image quality for automated TF scoring. TF scores from this subset were used 
to address scoring heterogeneity between TMA cores and whole sections for the same tumor. 
Human-based TF scoring was done by one observer (obs1) on H&E stained tissues. On TMA 
cores, TF was scored using all available magnifications and on the area of highest fragmentation 
for the TCGA and WS cohorts, under a magnification of 50x. This corresponded to 1920x1036 
pixels (3.5x1.9mm) for TCGA image frames and to 4mm FOV for WS with light microscopy. Two 
additional observers (obs2-3) evaluated 20% of the TCGA images (n=67) to address inter-
observer variability. 
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Sample preparation for mass spectrometry 
A total of 48 samples from the whole sections cohort were selected for mass spectrometry 
based on the availability of at least 1 tumor paraffin block containing >80% carcinoma epithelia 
per total tissue surface. Two 20µm thick microtome cuts were deparaffinized in xylene and 
washed with 96% ethanol. Samples were suspended in 120µl of SDS buffer (4% SDS, 100mM 
Tris / HCL pH 8.2, 0.1M DTT – dithiothreitol) and boiled at 95°C for 20 minutes followed by 2h 
at 80°C and processed with High Intensity Focused Ultrasound (HIFU) for 10 min, setting the 
ultrasonic amplitude to 65%. Protein concentration was determined using the Qubit® Protein 
Assay Kit (Life Technologies, Zurich, Switzerland). For each sample, 20µg protein were taken for 
on-filter digestion using an adaptation of the filter-aided sample preparation (FASP) protocol 
(74). Briefly, proteins were diluted in 200µl of UT buffer (Urea 8M in 100mM Tris/HCL pH 8.2), 
loaded on Ultracel 30000 MWCO centrifugal unit (Amicon Ultra, Merck, Darmstadt, Germany) 
and centrifuged at 14000g. SDS buffer was exchanged by one centrifugation round of 200µl UT 
buffer. Alkylation of reduced proteins was carried out by 5 min incubation with 100µl 
iodoacetamide 0.05M in UT buffer, followed by three 100µl washing steps with UT and three 
100µl washing steps with NaCl 0.5M. Finally, proteins were on-filter digested using 120µl of 
0.05 triethylammonium bicarbonate buffer (pH 8) containing trypsin (Promega, Madison, WI, 
USA) in ratio 1:50 (w/w). Digestion was performed overnight in a wet chamber at room 
temperature. After elution, the solution containing peptides was acidified to a final 0.1% TFA, 
3% acetonitirile concentration. Peptides were desalted using self-packed C18 Stage-Tips, dried 
and re-solubilized in 15µl of 3% acetonitrile, 0.1% formic acid for MS analysis. 
Liquid chromatography-mass spectrometry analysis 
Mass spectrometry analysis was performed on an Orbitrap Fusion mass spectrometer (Thermo 
Fisher Scientific, Waltham, MA, USA) coupled to an Eksigent-Nano-HPLC system (Sciex, 
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Framingham, MA, USA). Solvent composition at the two channels was 0.1% formic acid for 
channel A and 0.1% formic acid, 99.9% acetonitrile for channel B. For each sample 2μL of 
peptides were loaded on a self-made column (75μm × 150mm) packed with reverse-phase C18 
material (ReproSil-Pur 120 C18-AQ, 1.9μm, Dr. Maisch GmbH, Ammerbuch, Germany) and 
eluted at a flow rate of 300nL/min by a gradient from 3 to 25% B in 65 min, 35% B in 5 min and 
97% B in 5 min. Samples were acquired in a randomized order. The mass spectrometer (Tune 
page v1.1) was configured to fragment peptide precursor ions in data-dependent mode, 
allowing a maximum of 3 s between the full-scan spectra (top speed mode). Full-scan MS 
spectra (300–1500 m/z) were acquired at a resolution of 120000 at 200 m/z after accumulation 
to an automated gain control (AGC) target value of 400000. Wide quadrupole isolation was 
used, and an injection time of 50ms was set. Precursors with an intensity above 5000 were 
selected for MS/MS. Ions were isolated using a quadrupole mass filter with 1.6 m/z isolation 
window and fragmented by higher-energy collisional dissociation (HCD) using a normalized 
collision energy of 30. Fragments were detected in the linear ion trap using adapted “Universal 
Method” settings: the scan rate was set to Rapid, the automatic gain control was set to 100 
ions and the maximum injection time was 250 milliseconds. Charge state screening was enabled 
and singly and unassigned charge states were rejected. Precursor masses previously selected 
for MS/MS measurement were excluded from further selection for 25 seconds, and the 
exclusion window was set at 10 ppm. The samples were acquired using internal lock mass 
calibration on m/z 371.1010 and 445.1200. 
Protein identification and label free protein quantification 
Protein label-free quantification was performed using the software Progenesis QI for 
proteomics (v.4.0.4265.42984) software (Nonlinear Dynamics, Newcastle upon Tyne, UK), using 
as reference for alignment the raw-file of the pool sample. Normalization was kept with default 
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settings. From each Progenesis peptide ion (default sensitivity in peak picking) a maximum of 
the top five tandem mass spectra were exported into a Mascot generic file using charge 
deconvolution and deisotoping option and a maximum number of 200 peaks per MS/MS. This 
Mascot generic file (mgf) was searched with Mascot 2.4.3.3 (Matrix Science Ltd., London, UK) 
against the forward Uniprot database for Homo sapiens, concatenated to a reversed decoyed 
FASTA database and 260 common mass spectrometry protein contaminants. The parameters 
for precursor tolerance and fragment ion tolerance were set to ± 10 ppm and ± 0.6 Da. Enzyme 
was set to trypsin and one missed cleavage was allowed. Carbamidomethylation of cysteine 
was set as fixed modification, while oxidation (M) and deamidation (N, Q) were set as variable. 
The resulting .dat file was loaded into Scaffold v4.1.1 (Proteome Software) and filtered at 
peptide and protein False Discovery Rates (FDRs) were set to 1% and 9%, respectively. Finally, 
the Scaffold Spectrum Report was imported back into Progenesis. For quantification, all 
proteins identified with at least two peptide ions were assessed, resulting in an estimated 
protein FDR of 0.5%. Proteins were grouped with Progenesis and the relative quantification 
using Hi-N (N=3) peptides was used. For protein quantification, the average of the normalized 
abundance from the most intense N peptide ions of each protein group was calculated 
individually for each sample. This generated the normalized quantitative protein abundance. 
Protein levels were further log2 transformed for statistical testing. Differentially expressed 
proteins were identified by Significance Analysis of Microarrays as described (75). TF scores 
were log2 transformed and addressed as quantitative response using the standard regression 
method on median centered protein levels. Proteins significantly correlated with TF scores 
(FDR<0.05) were considered for further analysis. Gene ontology enrichment analysis was 
performed using WEB-based GEne SeT AnaLysis Toolkit (76) using default settings. All identified 
proteins (n=2614) were used as background (see original article). 
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Gene ontology enrichment networks and pathway analysis for TCGA mRNAseq data 
Analysis-ready standardized TCGA mRNA-Seq data was downloaded from the Broad GDAC 
Firehose stddata__2015_11_01 run. Two groups showing clearly distinguishable TF profiles on 
TCGA H&E stainings, consisting of patients with the 25% lowest (TF <6) and 25% highest (TF 
>18) scores were selected for mRNA differential expression analysis. For statistical testing, the 
R-package EdgeR was used to compare them. In total mRNAseq data for 20531 genes was 
available. Genes with a minimum of 1 count-per-million, in at least half of the samples, were 
selected (n=14151). Default parameter settings were applied. Candidates having a FDR <0.05 
were included in the gene ontology enrichment analysis. Gene ontology enrichment map was 
generated with the software Cytoscape (77) using BINGO (78) and Enrichment Map (79) 
plugins. Genes upregulated in high and low TF tumors, respectively, were uploaded separately 
in BINGO. Enrichment analysis was performed with the default hypergeometric test using a 
significance level <0.05 after Bonferroni correction for multiple testing. Enrichment map was 
generated using BINGO outputs for each tumor morphotype with the following parameter: p-
value cutoff <0.001, FDR <0.05, Jaccard coefficient=0.25. The generated network is represented 
by nodes (gene sets), edges (mutual overlap) and colors (tumor morphology groups: blue=low 
TF, red=high TF). Pathway analysis was done using the KEGG database (80) through WEB-based 
GEne SeT AnaLysis Toolkit.  
Data interpretation and statistical analysis 
All statistical analyses were performed on SPSS version 22 software (SPSS Inc., Chicago, USA). 
Relapse-free survival was measured from the date of surgery to the date of documented 
relapse or death as described (81). RFS was assessed only for patients who presented no 
evidence of remaining tumor (incomplete resection and/or metastases) after surgery. Kaplan 
Meier survival curves were evaluated using log-rank tests using TF scores dichotomized at the 
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median. Hazard ratios were assessed by Cox regression. Clinical correlations were addressed 
using the non-parametric spearman’s rank correlation test. The association of clinical 
parameters with survival was computed by univariate Cox regression. In addition, clinically 
relevant parameters were introduced into multivariate Cox regressions. P-values <0.05 were 
considered significant. 
Results 
LSCC shows a variable degree of tumor fragmentation 
Tumor fragmentation (TF) scores were automatically computed as the total number of tumor 
fragments in pan-cytokeratin stained TMAs of 208 LSCC patients and whole sections (WS) of 99 
patients (Table 1). The size of tumor fragments within individual tumors varied considerably 
(Figure 1A). By using X-ray microtomography we saw that tumor fragments represent 
projections of interconnected epithelial branches from a three dimensional perspective (Figure 
1B). The distribution of the computed TF scores was comparable in the TMA and WS cohorts 
(Figure S1A-B left). The assessment of a subset of 77 patients from WS with matching TMA 
cores from a secondary TMA, showed a positive correlation of TF scores between whole 
sections and tumor cores from the same tumor (c.coeff=0.484, p<0.001). However, due to 
intra-tumor heterogeneity the WS analysis allows a more reliable assessment of TF scores as 
demonstrated by the correlation analysis of computed TF scores from two tumor regions 
(Figure S1A-B right). We further tested the applicability of TF scoring by human eye using H&E 
stained images of the TMA and WS cohorts, as well as in an external TCGA LSCC cohort with 
similar clinical characteristics. The distribution of TF scores was comparable between the 
computed and human-based evaluations (Figure S1C-E). Histological examples of tumors with 
high and low fragmentation from TMA, WS and TCGA cohorts are shown in Figure 2.  
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Table 1: Patient cohorts. Summary of clinico-pathologic parameters including OS and RFS for TMA, WS and TCGA 
datasets. CI=95% confidence interval; TF computer/human=tumor fragmentation scores respectively computed 
or assessed by eye. 
Patient cohorts TMA WS TCGA 
Age       
 median (range) 66 (18 - 87) 65 (40 - 87) 68 (39-90) 
Sex       
 female 42 (20%) 19 (19%) 83 (25%) 
 male 166 (80%) 80 (81%) 252 (75%) 
pT        
 1 43 (21%) 24 (24%) 68 (20%) 
 2 107 (51%) 29 (29%) 213 (64%) 
 3 43 (21%) 34 (35%) 40 (12%) 
 4 15 (7%) 12 (12%) 14 (4%) 
pN        
 0 110 (53%) 47 (48%) 209 (63%) 
 1 73 (35%) 31 (31%) 88 (27%) 
 2 - 3 25 (12%) 21 (21%) 35 (10%) 
pM        
 0 196 (94%) 95 (96%) 284 (98%) 
 1a/b 12 (6%) 4 (4%) 5 (2%) 
Stage       
 I 71 (34%) 24 (24%) 165 (49%) 
 II 76 (37%) 35 (35%) 108 (32%) 
 III 50 (24%) 36 (37%) 57 (17%) 
 IV 11 (5%) 4 (4%) 5 (2%) 
Grade       
 1 - 2 121 (58%) 44 (44%) - - 
 3 87 (42%) 55 (56%) - - 
Size (cm)       
 median (range) 3.9 (0.4 - 14.0) 5 (1.1 - 11.0) - - 
Vessel infiltration       
 absent 122 (59%) 52 (53%) - - 
 present 86 (41%) 47 (47%) - - 
Adjuvant therapy       
 no 133 (64%) 69 (70%) 304 (91%) 
 yes 75 (36%) 30 (30%) 31 (9%) 
TF score       
 Computer (IHC) 
    
  
median (range) 7 (2-38) 984 (163-6093) 
 Human (H&E) 
      
median (range) 6 (2-40) 25 (2-132) 12 (1-68) 
OS (months)       
 median (CI) 42 (29 - 55) 52 (36 - 69) 56 (43-69) 
 follow-up max 169  137  157  
RFS (months)      
 median (CI) 59 (40-78) 46 (27-65) 75 (45-105) 
 follow-up max 169  137  154  
Total patients (n=642) 208   99   335   
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Figure 1: Computer-based morphometric analysis of tumor fragmentation. A) Left: histological whole section 
showing a squamous cell carcinoma of the lung stained with pan-cytokeratin IHC (brown) and its surrounding 
stroma (blue-grey counterstain). Right: color-based segmentation showing tumor fragments of different sizes 
labelled on a 32-colors scale. Approximate sizes are: single cell 200µm2, buds ≤800µm2, nests ≤3000µm2, larger 
fragments >3000µm2. Number of epithelial elements=32, sizemean=44’000µm2, sizemedian=14’000µm2. Scale bar: 
500µm. B). Left: X-ray microtomography 2D reconstructed slice of a lung SCC example. Arrows indicate epithelial 
tumor fragments, t*=tumor, n*=necrosis, s*=stroma. Right: 3D rendering of the tumor microarchitecture imaged 
by X-ray microtomography. 
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Figure 2: Lung squamous cell carcinoma microarchitecture and fragmentation. Histological examples of pan-
cytokeratin stained sections from TMA (A-B) and WS (C-D) cohorts. E-F) H&E stained sections from TCGA. 
Left/right: low/high fragmentation. 
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Tumor fragmentation is associated with increased invasiveness and worse outcome 
Clinico-pathologic correlations showed that high TF was consistently associated with vessel 
infiltration on both TMA and WS (Table S2). Perineural and mediastinal invasion were further 
evaluated on WS and positively correlated with TF as well (p=0.001, p=0.004 respectively). 
Survival analysis showed that high TF is a poor prognostic factor for OS and was confirmed using 
the external TCGA cohort with human-based scores (Figure 3).  
 
Figure 3: Overall survival curves based on tumor fragmentation. Kaplan Meier curves stratified by high/low TF, 
dichotomized at the median. HR=hazard ratio; CI=95% confidence interval. Computed TF scores were quantified 
on pan-cytokeratin stained tissue; Human-based scores were performed on H&E stained tissue. 
 
Increasing TF scores had a significantly poor impact on OS as showed by both univariate and 
multivariate analysis (Table 2). Analysis for relapse free survival showed comparable results for 
the three patient cohorts (Table S3). Human-based scores showed similar results for WS (Table 
S4). By evaluating the subset of 77 patients from WS with matching TMA cores, we observed a 
decrease of prognostic power using TMA cores (OS/RFS: p=0.060/0.152), in comparison with 
whole sections (OS/RFS: p<0.001/<0.001), possibly due to the higher impact of intra-tumor 
heterogeneity on the TMA. TF scores using different minimal fragment size thresholds were 
also evaluated on WS. The prognostic relevance of TF was similar for a wide range of size cutoffs 
(5-100 cells) for both OS and RFS (Figure S2).  
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Table 2: Association of TF scores on whole sections with overall survival. Survival analysis by Cox univariate and 
multivariate regressions. HR=hazard ratio; CI=95% confidence interval. Computer: automatic scoring on pan-
cytokeratin IHC stained tissue; Human: fragmentation scored by eye; TF (low/high): scores dichotomized at the 
median (categorical); TF (continuous): score as continuous variable. 
OS   univariate     multivariate   
TMA (n=208) HR 95% CI p-value HR 95% CI p-value 
TF (low/high) computer IHC 1.56 (1.12-2.16) 0.008 - - - 
TF(continuous) computer IHC 1.05 (1.02-1.07) <0.001 1.03 (1.01-1.06) 0.018 
Stage [I, II, III, IV] 1.56 (1.29-1.90) <0.001 1.45 (1.19-1.76) <0.001 
Grade [1,2,3] 1.34 (0.97-1.85) 0.075 1.20 (0.87-1.66) 0.266 
Vessel infiltration 2.63 (1.89-3.65) <0.001 1.64 (1.64-3.25) <0.001 
WS (n=99) HR 95% CI p-value HR 95% CI p-value 
TF (low/high) computer IHC 2.06 (1.26-3.37) 0.004 - - - 
TF(continuous) computer IHC 1.00 (1.00-1.00) <0.001 1.00 (1.00-1.00) 0.020 
Stage [I, II, III, IV] 1.81 (1.31-2.49) <0.001 1.54 (1.08-2.20) 0.016 
Grade [1,2,3] 1.76 (1.10-2.82) 0.018 1.45 (0.88-2.39) 0.144 
Vessel infiltration 1.99 (1.23-3.24) 0.005 1.22 (0.71-2.09) 0.480 
TCGA (n=335) HR 95% CI p-value HR 95% CI p-value 
TF (low/high) human H&E 1.97 (1.40-2.77) <0.001    
TF (continuous) human H&E 1.02 (1.01-1.03) 0.001 1.02 (1.01-1.03) 0.001 
Stage [I, II, III, IV] 1.25 (1.02-1.53) 0.030 1.26 (1.03-1.54) 0.025 
Grade [1,2,3] - - - - - - 
Vessel infiltration - - - - - - 
 
Tumor fragmentation is associated with changes in extracellular matrix 
We selected TCGA patients with the upper and lower quartiles of TF scores to identify molecular 
characteristics associated with TF morphotypes and identified 910 genes associated with the 
high TF. Enriched biological processes involved tissue development, extra-cellular matrix (ECM) 
organization and cell adhesion processes (Figure S3). KEGG analysis notably showed an 
upregulation of pathways involved in ECM-receptor interaction, focal adhesion and protein 
digestion. In parallel, mass spectrometry-based label-free quantification identified 154 proteins 
significantly associated with increased TF (Table S5, see original publication) including 
extracellular (20%) and cytoskeletal (15%) components. In accordance with mRNA-Seq analysis, 
we observed an enrichment of genes involved in developmental processes. 
In contrast, low TF was associated with 554 genes involved in diverse metabolic pathways 
including xenobiotics metabolism (Figure S3), and 205 proteins representing in majority 
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intracellular (70%) and nuclear proteins (46%). Biological nodes associated with decreasing TF 
were mostly related to hormone regulation processes.  
We validated the expression of Periostin and Versican, two ECM proteins associated with TF in 
both RNA and protein analyses, by immunohistochemistry (IHC). The expression of both 
proteins in the tumor and stromal compartments was significantly associated with TF (Figure 
4). 
 
 
Figure 4: Versican and Periostin immunohistochemistry. Boxplots showing IHC scores for Versican and Periostin 
compartmentalized expression in tumor and stroma grouped by high and low TF scores dichotomized at the 
median. B) Matching IHC stained tumor cores. Scale bar: 100µm. 
Discussion 
LSCC is histologically characterized by a variable degree of keratinization and/or the formation 
of intercellular bridges between tumor epithelial cells. Collective cell migration is predominant 
in LSCC as other invasion modes such as EMT (epithelial-mesenchymal transition, fibroblastoid) 
or amoeboid are less observed probably due to the tight desmosomal adhesions (82, 83). This 
invasion pattern results in an apparent network of epithelial branches in 3D, which is 
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histologically depicted by a high variability of epithelia sizes in 2D. In this study, we used an 
image-based computational method to quantify such tumor fragments, hypothesizing that high 
fragmentation is a trait of increased tumor invasiveness. In support of this hypothesis, we 
showed that TF was associated with increased blood vessel, mediastinal and perineural invasion 
and worse patient outcome. Consistently, molecular analysis showed an upregulation of 
processes involved in ECM remodeling and focal adhesion, major characteristics of increased 
cellular motility (83-86). The association of TF with two identified ECM proteins, Periostin and 
Versican, was validated by immunohistochemistry. Periostin is a secreted ECM protein is 
observed in the desmoplastic stroma of a variety of cancers and known to promote cell invasion 
(87-90). It is also involved in cardiac remodeling after myocardial infarction (91). Versican is a 
major proteoglycan of the extracellular matrix upregulated in several tumor types including 
lung cancer (92) and has been notably associated with poor prognosis in NSCLC (93). It is also 
shown to favor tumor metastasis in Lewis lung carcinoma cell lines (94). In contrast, tumors 
with low TF showed an enrichment of diverse metabolic and xenobiotic processes notably 
contributing to the regulation of a number of chemotherapeutic drugs (95-97). 
TNM staging is the only established system for predicting LSCC prognosis, whereas the value of 
tumor grading along the keratinization qualifier remains unclear. In this study, we evaluated 
the clinical relevance of LSCC stratification based on TF. Survival analysis showed that high TF 
is a poor prognostic marker independent from stage. This could be a useful additional grading 
parameter suggesting tumor invasiveness. Alternative histological parameters such as tumor 
budding have been proposed as various measures of tumor invasion in cancers notably in 
colorectal carcinoma (98-100). In NSCLC, single cells, tumor buds (<5 cells) or nests (≤15 cells) 
together with stroma thickness have also shown an impact on patient’s survival (53-56), 
although small invasive tumor clusters are less frequent in LSCC. As shown in Figure 1, the 
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typical median and average LSCC epithelia clusters size in 2D is at least one order of magnitude 
higher than single cells and tumor buds.  Furthermore, studies of the 3D tumor 
microarchitecture suggest that single cells may be part of tumor buds, which in turn may belong 
to larger tumor nests or branches (101). 
Alternatively, current progresses in digital pathology have led to automated identification of 
prognostic features on histological sections, notably for non-small cell lung cancer (102). 
However, such methods are mostly based on the quantification of cellular (mostly nuclear and 
cytoplasmic) features. Our computational method is focused on a higher order feature of the 
tumor epithelia, related to tumor invasion patterns, which can be favorably translated into a 
human-based scoring system on H&E tissue staining. The proposed computational image-based 
analysis allowed unbiased scoring of tumor fragments, but has nevertheless intrinsic 
limitations. The main drawback is that normal epithelial lung structures as well as necrotic 
residues are also immune-reactive with pan-cytokeratin. To minimize false positive tumor 
fragments, adjacent normal tissue was covered and a minimal size threshold for tumor 
fragments (>800µm2) was set. Finally, the clinical relevance of TF in the context of adjuvant 
therapy could not be addressed in this study, because of the high heterogeneity of treatment 
modalities across cohorts.  
In conclusion, we have shown using an image-based computational approach, that high 
fragmentation of LSCC is a histologic trait associated with increased aggressiveness. In addition, 
the integration of molecular data showed an upregulation of proteins favoring extracellular 
matrix remodeling and focal adhesion, supporting the increased invasive potential of tumors 
with such high fragmentation. The proposed histologic parameter is an independent 
unfavorable prognostic marker that could be envisaged as new grading parameter for LSCC.  
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Supplementary figures 
 
Figure S1: Frequency distributions, intra-tumor heterogeneity and inter-observer variability for TF scores. A) 
Percentage distribution of computed TF scores for TMA and correlation between matching cores. B) Percentage 
distribution of computed TF scores for WS and correlation between matching whole sections. C) Percentage 
distribution of human-based TF scores for TMA and correlation between matching cores. B) Percentage 
distribution of human-based TF scores for WS and correlation between matching whole sections. E) Percentage 
distribution of human-based TF scores for TCGA images from observer 1 (Obs1) and correlations between the 
three observers on a subset of pictures (n=67). Dashed line indicates the median. 
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Figure S2: Threshold analysis of tumor fragmentation in correlation with RFS and OS. Series of cox univariate survival 
analyses are represented for the WS cohort. Data points represent single survival analyses repeated for computed 
TF scores using different tumor fragments size cut-offs. X-axis indicates the minimal size threshold for tumor 
fragments. Y-axis are the corresponding p-values. Black line indicates p=0.05. 
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Figure S3: Biological processes associated with TF morphotypes from TCGA mRNAseq and WS Mass Spectrometry 
data. A) gene ontology network visualization of RNAs overexpressed in high (red) and low TF (blue) groups. B) bar 
plot showing molecular pathways associated with low (blue) and high (red) TF, at the RNA level. C) bar plot showing 
biological processes (BP) associated with increasing (red) and decreasing (blue) TF, at the protein level. Numbers 
indicate protein counts per category; asterisks* indicate BPs also enriched at the RNA level. 
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Supplementary tables 
 
Table S2: Association of tumor fragmentation with clinico-pathological parameters. 
  TMA (n=208) WS (n=99) TCGA (n=335) 
  low 
TF 
high 
TF 
p-value  p-value low 
TF 
high 
TF 
p-value  p-value low TF high 
TF 
p-value  p-value 
    <med >=med low/high continuous <med >=med low/high continuous <med >=med low/high score 
Age   0.834 0.858   0.460 0.387   0.843 0.939 
 median 67 66   64 66   68 69   
Sex   0.084 0.414   0.001 0.005   0.269 0.88 
 female 12.0% 8.2%   3.0% 16.2%   13.4% 11.4%   
 male 35.1% 44.7%   46.5% 34.3%   35.5% 39.7%   
pT   0.837 0.793   0.104 0.001   0.313 0.944 
 1 11.1% 9.6%   16.2% 8.1%   10.1% 10.1%   
 2 22.1% 29.3%   15.2% 14.1%   30.8% 32.8%   
 3 10.6% 10.1%   15.2% 19.2%   6.9% 5.1%   
 4 3.4% 3.8%   3.0% 9.1%   1.2% 3.0%   
pN   0.801 0.487   0.725 0.321   0.968 0.958 
 0 23.6% 29.3%   25.3% 22.2%   30.7% 32.2%   
 1 19.2% 15.4%   15.2% 16.2%   13.0% 13.6%   
 2-3 4.3% 8.2%   9.1% 12.1%   5.4% 5.1%   
pM   0.698 0.669   0.061 0.072   0.173 0.090 
 0 44.7% 49.5%   49.5% 46.5%   49.8% 48.5%   
 1a/b 2.4% 3.4%   0.0% 4.0%   0.3% 1.4%   
Stage   0.804 0.756   0.113 0.009   0.305 0.772 
 I 15.4% 18.8%   15.2% 9.1%   22.7% 26.6%   
 II 19.2% 17.3%   18.2% 17.2%   17.6.% 14.6%   
 III 10.6% 13.5%   16.2% 20.2%   8.4% 8.7%   
 IV 1.8% 3.4%   0.0% 4.0%   0.3% 1.2%   
Grade   0.262 0.090   0.012 0.008   - - 
 1-2 29.4% 28.8%   28.3% 16.2%   - -   
 3 17.8% 24.0%   21.2% 34.3%   - -   
Size (cm)   0.068 0.311   0.586 0.013   - - 
 median 3.5 4   4.3 5.8   - -   
Vessel infiltration 0.017 0.008   0.003 0.001   - - 
 absent 31.7% 26.9%   33.3% 19.2%   - -   
 present 15.4% 26.0%   16.2% 31.3%   - -   
Adjuvant therapy  0.016 0.016   0.947 0.809   0.028 0.045 
 no 34.1% 29.8%   34.3% 35.3%   42.7% 48.0%   
  yes 13.0% 23.1%     15.2% 15.2%     6.3% 3.0%     
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Table S3: Association of TF scores with relapse-free survival. 
RFS   univariate     multivariate   
TMA (n=170) HR 95% CI p-value HR 95% CI p-value 
TF (low/high) computer IHC 1.64 (1.13-2.37) 0.009 - - - 
TF (continuous) computer IHC  1.05 (1.02-1.08) 0.002 1.04 (1.01-1.08) 0.010 
Stage [I, II, III, IV] 1.13 (0.87-1.46) 0.370 1.16 (0.88-1.52) 0.283 
Grade [1,2,3] 1.21 (0.83-1.76) 0.320 1.06 (0.71-1.57) 0.784 
Vessel infiltration 2.06 (1.41-3.02) <0.001 1.93 (1.31-2.84) 0.001 
WS (n=85) HR 95% CI p-value HR 95% CI p-value 
TF (low/high) computer IHC 2.29 (1.32-3.96) 0.003 - - - 
TF (continuous) computer IHC  1.00 (1.00-1.00) <0.001 1.00 (1.00-1.00) 0.072 
Stage [I, II, III, IV] 1.73 (1.22-2.45) 0.002 1.47 (1.00-2.16) 0.051 
Grade [1,2,3] 1.67 (1.03-2.72) 0.039 1.41 (0.83-2.38) 0.201 
Vessel infiltration 2.07 (1.23-3.48) 0.006 1.25 (0.67-2.33) 0.487 
TCGA (n=181) HR 95% CI p-value HR 95% CI p-value 
TF (low/high) computer IHC 2.08 (1.29-3.37) 0.003 - - - 
TF (continuous) computer IHC  1.02 (1.00-1.04) 0.028 1.02 (1.00-1.04) 0.016 
Stage [I, II, III, IV] 1.24 (0.90-1.69) 0.191 1.31 (0.94-1.81) 0.108 
Grade [1,2,3] - - - - - - 
Vessel infiltration - - - - - - 
 
Table S4: Association of human-based TF scores with OS and RFS. 
OS TMA (n=208) WS (n=99) 
univariate HR 95% CI p-value HR 95% CI p-value 
TF (high/low) human H&E 1.35 (0.97-1.88) 0.080 2.48 (1.49-4.11) <0.001 
TF (continuous) human H&E 1.05 (1.02-1.07) <0.001 1.00 (1.00-1.00) <0.001 
multivariate       
TF (continuous) human H&E 1.02 (0.99-1.05) 0.139 1.01 (1.00-1.02) 0.012 
Stage [I, II, III, IV] 1.46 (1.19-1.78) <0.001 1.53 (1.07-2.2) 0.020 
Grade [1,2,3] 1.22 (0.88-1.70) 0.224 1.65 (1.02-2.69) 0.043 
Vessel infiltration 2.37 (1.68-3.35) <0.001 1.16 (0.66-2.05) 0.611 
RFS TMA (n=170) WS (n=85) 
univariate HR 95% CI p-value HR 95% CI p-value 
TF (high/low) human H&E 1.12 (0.79-1.68) 0.450 1.67 (0.99-2.81) 0.056 
TF (continuous) human H&E 1.03 (0.99-1.07) 0.180 1.01 (1.00-1.02) 0.015 
multivariate       
TF (continuous) human H&E 1.01 (0.97-1.05) 0.554 1.01 (1.00-1.01) 0.339 
Stage [I, II, III, IV] 1.10 (0.84-1.44) 0.481 1.46 (0.98-2.16) 0.060 
Grade [1,2,3] 1.18 (0.81-1.73) 0.390 1.57 (0.95-2.60) 0.082 
Vessel infiltration 2.05 (1.39-3.03) <0.001 1.44 (0.80-2.61) 0.227 
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Abstract 
Introduction: Neoadjuvant chemotherapy is a treatment strategy aiming at reducing the tumor 
burden before surgery. In this setting, the amount of residual tumor burden is an important 
prognosticator although no regression scoring system is currently established. The integration 
of an image-based computational approach might provide a solid basis to measure reliably 
histopathologic regression.   
Methods: A computerized morphometric approach was applied on whole histological sections 
from lung squamous cell carcinomas (LSCC), in order to quantify four morphologic features 
related to the residual tumor burden after neoadjuvant chemotherapy (n=55 patients). A 
cohort of chemo-naïve patients (n=104) was used for comparison. Positron Emission 
Tomography / Computed Tomography (PET/CT) measurements (n=23) were integrated for 
subsequent correlation analysis against quantitative morphometric parameters. 
Results: After neoadjuvant chemotherapy, tumor area (Tumorarea), the percentage of tumor 
cells (Tumor%) as well as the amount (TF) and size of the largest residual fragment (Sizemax) were 
significantly reduced compared to chemo-naïve LSCC. All four parameters significantly 
correlated with the maximum standard uptake value after neoadjuvant treatment. Survival 
analysis showed that Tumor%, Tumorarea and Sizemax were adequate parameters to stratify 
patients into risk categories based on a 3-years overall survival cutoff, whereas TF was the only 
significant parameter for chemo-naïve LSCC. 
Conclusions: In this study, we emphasized the clinical relevance of using an image-based 
computational approach, to quantify histopathologic response after neoadjuvant 
chemotherapy. We believe this approach is not restricted to LSCC or to a particular treatment, 
and could therefore be a valuable method for quantitative pathologic readout of treatment 
success.  
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Introduction 
In a neo-adjuvant setting, chemotherapy is given before surgery, as it may result in significant 
reduction of the tumor burden enabling radical resection in otherwise not operable patients. 
This treatment strategy has been shown to improve overall survival (OS) (103) and recurrence-
free survival in resectable NSCLC (104). The classification of malignant tumors is done by the 
TNM staging (primary tumor, lymph node involvement and distant metastases) which is crucial 
for prognosis evaluation and treatment decisions (21). Although there is no WHO-accepted 
consensus for regression scoring of NSCLC, whereby the extent of residual vital tumor epithelial 
cells and the amount of fibrosis may be important parameters. Several regression systems have 
been proposed based on the percentage of remaining tumor cells (105-107) or the area of 
residual tumor (108).  
However, previously proposed tumor regression scoring methods (TRS) relied on a semi-
quantitative and subjective pathologic evaluation. The automatic quantification of morphologic 
parameters related to the amount and size of residual tumor tissue could be useful for 
improving and standardizing current tumor regression schemes in NSCLC (109).  
In our study, we have evaluated two clinical cohorts of lung squamous cell carcinoma (SCC), the 
second most frequent histologic subtype of NSCLC. We have previously proposed an approach 
to quantify tumor fragmentation of LSCC, a structural feature related associated with increased 
tumor invasion (66). In this study, we aimed at extending our approach to quantify structural 
histologic changes after neoadjuvant chemotherapy (NAC). For this purpose, four histologic 
parameters (total tumor surface, tumor/stroma percentage as well as the amount and size of 
the largest residual tumor fragment) were compared between two patient cohorts, having 
received NAC or not. 
 
 
53  
Materials and Methods  
Patient cohorts 
In this retrospective study, patients with diagnosed primary lung SCC at the University Hospital 
Zurich were selected. Patients with non-squamous non-small cell lung cancer (NSCLC), 
synchronic or metachronic second primary tumor or with overall survival (OS) < 1 month post-
surgery were excluded. Squamous cell differentiation was assessed on haematoxylin-eosin 
(H&E) and alcian blue-periodic acid schiff (AB-PAS) stains. Poorly differentiated SCC were 
verified by immunohistochemistry (IHC) using TTF1, p40, p63, CK7 and synaptophysin 
antibodies. Two clinical cohorts were selected separately in this study. The chemo-naïve cohort 
consisted of 179 patients diagnosed with lung SCC between January 2003 and June 2010 having 
complete clinical data. After revision for exclusion criteria, 104 patients were included. The 
neoadjuvant group consisted in 58 patients diagnosed with lung SCC between February 2000 
and September 2012, undergoing surgery after neo-adjuvant chemotherapy at the University 
Hospital Zurich. After revision for exclusion criteria, 55 patients remained in this cohort. This 
study was approved by the Ethical Commission of the Canton of Zurich under reference number 
KEK ZH-Nr. 29-2009/14.  
Histopathological samples preparation 
For each cohort, two tissue blocks showing representative tumor areas were selected from H&E 
stained diagnostic cases. For few neoadjuvant treated cases, when the remaining tumor area 
was too small, only one whole section was selected. IHC was performed using mouse 
monoclonal anti-human cytokeratin AE1/AE3 (M3515, DAKO, dilution 1:50) on an automated 
platform (Ventana Medical Systems, Tucson, AZ, USA). The following detection was finalized 
with a secondary antibody and the OptiView DAB kit (Ventana Medical Systems). IHC stained 
sections were scanned using a high-resolution whole slide scanner (Nanozoomer Digital 
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Pathology, Hamamatsu, Japan) using a 40x objective with spatial resolution of 0.23µm/pixel. 
Tumor tissue was manually annotated by a surgical pathologist (A.S.) in order to exclude 
surrounding non-tumor lung tissue from the analysis.  
Image processing and regression scoring 
A color threshold was used to segment malignant tumor tissue (brown positive signal) from its 
surrounding desmoplastic stroma (blue-grey counterstain) using Fiji (73). The same method 
was used in (66). Morphologic parameters of the resulting segmentation masks were further 
extracted and quantified for each disconnected carcinoma fragment larger than 800µm2. For 
each tumor specimen, the total surface covered by tumor cells (Tumorarea), the percentage of 
tumor cells (Tumor%), the total number of tumor fragments (TF) and the size of largest 
fragment (Sizemax) were averaged from two histologic sections. Scores for cases with only one 
available tissue section were duplicated. For chemo-treated cases with extensive necrosis 
showing unspecific staining, tissue segmentation was performed by trainable algorithms using 
the software inForm Tissue Finder™ (PerkinElmer, Waltham, MA, USA) (Figure S1). Histologic 
regression scores were evaluated by eye on the two available tissue blocks, using a 
continuous scale (range: 0-100%). The tumor regression score (TRG) was evaluated for each 
case on the whole tissue collection, following criteria proposed by Junker et al.: TRGI=<10% 
regression, TRGIIa=[10-90]% regression, TRGIIb=>90% regression, TRGIII=100% regression. 
PET/CT acquisition and analysis 
Patients from the NAC cohort with available FDG PET/CT before and after neoadjuvant 
treatment (before tumor resection) were analyzed. Patients’ inclusion criteria was: 
acceptable quality of FDG PET/CT scans, not elevate blood glucose, fasting for at least 4 
hours, FDG uptake time within 45-60 minutes and adequate FDG injection (< 100 MBq 
difference between both FDG injections). The detailed protocol is explained in (110). 
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Data interpretation and statistical analysis 
All statistical analyses were performed on SPSS version 22 software (SPSS Inc., Chicago, USA). 
Overall survival (OS) and relapse-free survival (RFS) were evaluated from the date surgery to 
the date of death or documented relapse or as described (81). Only patients with no evidence 
of remaining tumor after surgical resection of the primary tumor were included in RFS 
calculations. Differences between NAC and NC morphologic parameters were addressed using 
the Mann-Whitney U test. Correlations between PET metrics (SUVmax, BSL, BSV) and 
morphologic parameters (Tumorarea, Tumor%, TF, Sizemax) were calculated using the non-
parametric Spearman’s rank correlation test. A receiver operator characteristic (ROC) curve 
was generated for each morphologic parameter using a cutoff of 3 years RFS to separate 
short and long-term survivors. The area under the ROC curve (AUROC) was computed for 
each parameter. Patients with clinical follow-up shorter than 3 years were omitted in the ROC 
analysis. The optimal cut off point was determined for each parameter with the point that 
minimizes the distance to the (0,1) corner in the ROC plane (111). Mean overall survival and 
Kaplan-Meier p-values were calculated using the Log Rank test. Hazard ratios were retrieved 
by univariate cox regression. P-values <0.05 were considered significant. 
Results 
The frequency of clinic-pathologic parameters for both cohorts is summarized in Table 1. Both 
NAC and CN cohorts showed similar clinical parameters. In all cohorts, staging, lymph node 
involvement and distant metastasis were prognostic parameter. Particularly, in the NAC cohort, 
ypN0 and ypN1 had similar mOS (>80 months) whereas ypN2 subgroup had considerably 
shorter mOS (<26 months). Morphologic changes after NAC were compared with the CN group. 
Four morphologic parameters representing the total tumor cells surface (Tumorarea), the 
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percentage of tumor cells within the tumor area (Tumor %), the total number of tumor 
fragments (TF) and the largest fragment (Sizemax) were automatically quantified for all LSCC 
cases (Figure1).  
 
Figure 1: Computer-based morphometric analysis. A) Overview of a bronchial lung squamous cell carcinoma stained 
by pan-cytokeratin IHC. The non-malignant lung structures are masked by hand (glands, bronchus and cartilage). 
B) Corresponding segmentation mask of the tumor tissue. The tumor percentage in respect with the stroma, the 
tumor area, size of the largest fragment and number of fragments (TF) are computed.
 
 
57  
Table 1: Summary of clinico-pathologic parameters and mean OS. Legend: NAC=neoadjuvant chemotherapy, 
mOS=mean overall survival; CI=95% confidence interval; p=Log Rank test p-value; yp(T/N/M)=pathologic 
evaluation after chemotherapy. 
Clinical cohorts chemo treated (NAC) n=55 chemo-naïve n=104 
    N % mOS CI (95%) p N % mOS CI (95%) p 
Age         0.044         0.169 
  ≤62 33 (60%) 87.6 (67.6-107.5)   47 (45)% 75.6 (60.9-90.2)   
  >62 22 (40%) 55.6 (34.4-76.7)   57 (55)% 63.4 (50.3-76.5)   
Sex         0.897         0.187 
  female 12 (22%) 73.3 (44.8-101.8)   21 (20)% 53.7 (39.8-67.6)   
  male 43 (78%) 74.9 (56.7-93.1)   83 (80)% 71.5 (60.1-83)   
ypT/pT         0.612         <0.001 
  0 5 (9%) 87.4 (65.5-109.4)   0 (0)% - -   
  1 19 (35%) 70.5 (42-99.1)   24 (23)% 87.7 (70.1-105.4)   
  2 13 (24%) 79.2 (55.9-102.5)   34 (33)% 79.8 (63-96.5)   
  3 7 (13%) 48.5 (23.5-73.4)   34 (33)% 54.7 (40.1-69.3)   
  4 11 (20%) 43.3 (26.7-59.8)   12 (12)% 23.9 (9.9-37.9)   
ypN/pN         0.005         0.001 
  0 26 (47%) 81.5 (60.9-102)   49 (47)% 81.2 (67.1-95.3)   
  1 20 (36%) 82.0 (56.3-107.6)   34 (33)% 52.5 (38.6-66.3)   
  2 9 (16%) 25.9 (10-41.8)   20 (19)% 63.4 (40.8-86)   
  3 0 (0%) - -   1 (1)% 8.1 (8.1-8.1)   
ypM/pM         0.001         <0.001 
  negative 54 (98%) 75.8 (60.1-91.6)   100 (96)% 71.3 (61.3-81.3)   
  positive 1 (2%) 4.7 (4.7-4.7)   4 (4)% 7.2 (3.3-11)   
                        
Stage         <0.001         <0.001 
  0 5 (9%) 87.4 (65.5-109.4)   0 (0)% - -   
  I 13 (24%) 88.6 (59-118.2)   26 (25)% 89.8 (72.4-107.3)   
  II 15 (27%) 87 (62.2-111.7)   38 (37)% 69.7 (56.5-82.9)   
  III 21 (38%) 36 (23.5-48.4)   36 (35)% 51.2 (36.4-66.1)   
  IV 1 (2%) 4.7 (4.7-4.7)   4 (4)% 7.2 (3.3-11)   
Neoadjuvant chemotherapy         0.239         - 
  platinum+gemcitabine 19 (35%) 56.2 (32.6-79.8)   - - - -   
  platinum+taxane 26 (47%) 75.8 (57.1-94.6)   - - - -   
  platinum+other 10 (18%) 93 (52.9-133.1)   - - - -   
Cycles         0.904         - 
  2 3 (5%) 50.8 (12.6-89)   - - - -   
  3 43 (78%) 73.5 (55.8-91.2)   - - - -   
  4 7 (13%) 77.8 (47.1-108.6)   - - - -   
  5 2 (4%) 32.5 (14.5-50.5)   - - - -   
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The distribution of morphologic parameters was considerably different between the two 
cohorts and all four parameters were considerably reduced in NAC compared to CN (all 
p<0.001) (Figure 2A).  
 
Figure 2: Morphologic changes between neoadjuvant chemotreated and chemo-naïve LSCC. A) Boxplots showing 
quantitative morphologic features stratified by neoadjuvant chemotherapy (NAC) and chemo-naïve (CN) LSCCs. B) 
Histograms showing the distributions of the four morphologic parameters for CN LSCCs and NAC (C). Legend: 
Tumor%=percentage of tumor cells; Tumorarea=tumor cells area; Sizemax=size of the largest fragment; TF=number 
of fragments. 
 
ROC analysis of the four morphologic parameters showed that Tumor%, Tumorarea, and Sizemax 
were able to stratify NAC patients in two risk groups - using a 3-years OS cutoff - but not TF 
(Figure 3A). In addition, Stage, ypN and Tumor% were the most discriminant parameters and 
were superior than tumor regression scores performed by eye (Figure S2, left). In the ypN0-1 
subpopulation, Tumor% was the most significant parameter with the highest AUROC compared 
to the other morphologic parameters (Figure 3A) as well as Stage and ypN0-1 (Figure S2, right). 
This was confirmed by survival analysis (Table 2).  
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Table 2: Summary of morphologic parameters and mean OS for NAC patients. The computed parameters were 
dichotomized at the best cutoff point. Legend: NAC=neoadjuvant chemotherapy, mOS=mean overall survival; 
CI=95% confidence interval; p=Log Rank test p-value; TRG=tumor regression grade as described in (106); 
yp(T/N/M)=pathologic evaluation after chemotherapy. 
 
 NAC cohort all patients (n=55) ypN0-1 patients (n=46) 
    N % mOS CI (95%) p N % mOS CI (95%) p 
Tumor%     0.004     <0.001 
 <30% 38 (69%) 86.6 (68.6-104.5)  30 (65%) 100.9 (82.4-119.3)  
 ≥30% 17 (31%) 41.4 (18.2-64.5)  16 (35%) 43.5 (19.2-67.8)  
Tumorarea     0.039     0.013 
 <35 mm2 31 (56%) 87.0 (67.5-106.6)  24 (52%) 101.6 (81.2-122)  
 ≥35 mm2 24 (44%) 54.8 (33-76.6)  22 (48%) 59.3 (36.4-82.2)  
Sizemax     0.017     0.002 
 <21mm2 37 (67%) 85.5 (67.3-103.6)  29 (63%) 100 (81.2-118.7)  
 ≥21mm2 18 (33%) 47.9 (23.5-72.3)  17 (37%) 50.3 (24.8-75.7)  
TRG         0.603         0.733 
  1 10 (18%) 63.5 (29.4-97.6)   9 (20%) 70.4 (35.2-105.5)   
  2a 28 (51%) 73.6 (51-96.2)   22 (48%) 82.9 (57.2-108.6)   
  2b 12 (22%) 63.0 (36.7-89.3)   10 (22%) 71.3 (42.1-100.5)   
  3 5 (9%) 87.4 (65.5-109.4)   5 (11%) 87.4 (65.5-109.4)   
 
 
Kaplan Meier survival curves were represented for Tumor% at the best cutoff point (Figure 3B). 
Similar results were found using a 3 years RFS cutoff (Figure S3). In contrast, for CN patients, 
Tumor%, Tumorarea, and Sizemax were not significant parameters whereas TF was the best 
discriminative morphologic parameter using a 3 years RFS (p=0.030) and OS (p=0.051) (Figure 
S4).  
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Figure 3: ROC and survival analysis of morphologic parameters for NAC patients. A) Receiver operator characteristic 
curve was generated for the four morphologic parameters and 3-years overall survival, for all NAC patients (left) 
and pN0-1 (right). Dots show the best cutoff points for significant parameters. B) Kaplan Meier survival curve for 
Tumor%, the parameter with the largest area under the curve (AUC=0.83). Legend: NAC=neoadjuvant 
chemotherapy group; CI=confidence interval; Tumor%=percentage of tumor cells; Tumorarea=tumor cells area; 
Sizemax=size of the largest fragment; TF=number of fragments; HR=hazard ratio. 
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FDG PET-CT imaging data was retrieved for subset of NAC patients, before and after NAC 
treatment. Correlation analysis showed that SUVmax post-chemotherapy (before surgery) 
positively correlated with the four histologic parameters. Tumor area was the morphologic 
parameter best correlating with SUVmax, BSL and BSV post chemotherapy (p<0.01) (Figure 4). 
Interestingly, PET values before NAC treatment did not correlate with any morphologic 
parameter.  
 
Figure 4: Correlation matrix of FDG PET/CT and morphologic parameters. PET/CT values before and after NAC (n=23 
patients) were correlated with continuous morphologic values (n=55 patients). Correlation coefficients (Corr) are 
indicated with a corresponding color-scale: blue=negative, orange=positive. Correlations of PET values 
before/after NAC with morphologic parameters are highlighted by blue/red boxes. Legend: BSL=total lesion 
glycolysis (background subtracted); BSV=metabolic volume (background subtracted). 
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Discussion 
Neoadjuvant chemotherapy produces distinctive morphological changes of both tumor and 
stromal compartments often resulting in the reduction of tumor burden accompanied by an 
increase of the fibrotic stroma and necrosis and the infiltration of foam cell and macrophages 
(112). Several tumor regression models - based on the extent of residual vital tumor epithelial 
cells – have been proposed for NAC treated NSCLC, by means of classical pathology. Despite 
past efforts, there is still no currently established tumor regression system although the 
pathologic response could be a valuable surrogate for overall survival (113). Junker et al. 
proposed a regression scheme in 3 grades starting from a grade 1 defined as no or only 
spontaneous regression, a grade 2 as incomplete regression (2a with >10%, 2b with ≤10% vital 
tumor cells) and grade 3 as complete regression without any detectable vital cells (105, 106). 
Based on this, it has been showed that NSCLC with less than 10% of residual viable tumor cells 
(107, 114), a pathological complete remission (115-117) or a total residual tumor area ≤400 
mm2 (108) were favorable prognostic parameters. Alternatively, tumor-infiltrating lymphocytes 
might also predict response to chemotherapy for NSCLC (118). However, traditional pathology 
relies on visual examinations and semi-quantitative scoring methods. The automatic 
quantification of morphologic parameters could be a good indicator of the effectiveness of 
therapy in NSCLC (109).  
We focused our study on morphologic changes induced by NAC for lung squamous cell 
carcinoma (LSCC). Unlike adenocarcinoma which can present five distinct morphologic patterns 
(47), LSCC is histologically mainly characterized by the presence of keratinization or basaloid 
features (21). We evaluated four potentially prognostic parameters by quantitative pathology, 
using a chemo-naïve cohort for comparative analysis. We showed that parameters related to 
the remaining tumor burden after NAC (tumor percentage, tumor area, size of the largest 
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fragment) are prognostic parameters. In contrast, these parameters were not prognostic in a 
chemo-naïve setting, whereas TF, a parameter reflecting tumor invasiveness, was prognostic 
only in this group. This suggests that differential tumor grading should be performed depending 
if the patient received a therapy prior to surgical resection.  
In addition, we observed an increase of prognostic power of morphologic parameters for cases 
without distant lymph node metastasis (N2). This suggests that histopathologic response at the 
primary site only is suboptimal for accurate regression evaluation. Although the presented 
parameters are highly associated to each other (figure 4), survival analysis suggested that 
tumor percentage might be a robust parameter to assess tumor regression. In addition, our 
quantitative method was more performant to stratify patients into high and low risk categories 
compared human-based regression scores.  
FDG PET/CT is a potentially valuable imaging modality to predict histologic response after 
neoadjuvant therapy (119).  
In our study, PET/CT analysis was performed using SUVmax, and background substracted values 
for the total lesion glycolysis (BSL) and metabolic tumor volume (BSV). We have previously 
shown that these parameters were correlated better with histopathologic tumor regression 
score in NSCLC than methods using a fixed threshold (42% SUVmax) (110). In this study, we 
showed that SUVmax measured after chemotherapy and before tumor resection significantly 
correlated with all morphologic parameters. However, PET values before neoadjuvant 
chemotherapy did not correlate with any morphologic parameter. This is in line with previous 
studies, showing that standardized uptake values correlate with histopathologic responses in 
NSCLC (120-125) whereas pre-chemo PET/CT might be insufficient to predict pathologic 
response in LSCC (122).  
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Our study has nevertheless several limitations. We presented a retrospectively and, due to the 
limited availability of NAC tumor specimens, no validation cohort could be analyzed. Therefore, 
before implementing a new tumor regression system, a larger clinical study needs to be 
performed. Furthermore, the morphometric analysis was performed using two tissue blocks 
showing remnants of tumor, whereas tissue blocks showing complete regression were ignored. 
For this reason, our Tumor% scores are virtually higher and cannot be directly compared with 
previously published pathologic scores. In addition, our study focused solely on squamous cell 
carcinoma of the lung, which is a subtype of NSCLC. As proposed by the Association for the 
Study of Lung Cancer (IASLC)/the American Thoracic Society (ATS)/the European Respiratory 
Society (ERS), adenocarcinoma can be grouped into five morphologic subtypes: lepidic, acinar, 
papillary, micropapillary and solid (47). However, these morphologic patterns of might 
significantly affect FDG uptake (126) and it has been shown that squamous cell carcinomas have 
higher SUV uptake than adenocarcinomas (127-131). Therefore, we deliberately included solely 
LSCC in our study, in order to study a homogeneous population by morphometric and PET 
analyses. 
In conclusion, our study suggests that quantitative pathology approaches may empower 
diagnostic power in pathology in particular to assess the pathologic response after treatment. 
Our approach is not restricted to LSCC and can be potentially applied to quantify histologic 
treatment response in other squamous cell carcinomas. 
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Supplementary figures 
 
Figure S1: Tumor tissue segmentation using trainable algorithms. A) Overview of a lung squamous cell carcinoma 
stained by pan-cytokeratin IHC. Scale bar: 10mm. B) 10x magnification, scale bar: 1000µm. C) Corresponding 
segmentation mask using the software inForm Tissue Finder™. Legend: T=tumor cells; S=stroma; U=unspecific 
staining, accounting for stroma; background: purple. 
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Figure S2: ROC and survival analysis of pathologic and morphologic parameters for NAC patients. Receiver operator 
characteristic curve was generated for Stage, ypN and histologic regression scores for all NAC patients (left) and 
ypN0-1 (right). Legend: NAC=neoadjuvant chemotherapy group; AUC=area under the curve; CI=confidence 
interval; Tumor%=percentage of tumor cells, computed; Regression%=percentage of regressed tumor tissue, 
scored by eye; TRG=tumor regression score (I, IIa, IIb, III), scored by eye, values were inverted in this plot; 
ypN=lymph node involvement.  
 
 
67  
 
Figure S3: ROC and relapse-free survival analysis of morphologic parameters for NAC patients. A) Receiver operator 
characteristic curve was generated for the four morphologic parameters and 3 year RFS, stratified by ypN0-1 (left) 
and ypN2(right). B) Kaplan Meier survival curve for Tumor%, the parameter with the largest area under the curve 
(AUC=0.76). Legend: NAC=neoadjuvant chemotherapy group; CI=confidence interval; Tumor%=percentage of 
tumor cells; Tumorarea=tumor cells area; Sizemax=size of the largest fragment; TF=number of fragments; HR=hazard 
ratio.  
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Figure S4: ROC and survival analysis of morphologic parameters for CN patients. A) Receiver operator characteristic 
curve was generated for the four morphologic parameters and 3 year overall survival and relapse-free survival. 
Below: area under the curve and corresponding lower-upper bound of the four parameters. Cases with clinical 
follow-up < 3years were omitted (n=3). Since there was no optimal cutoff point for TF, the median was chosen as 
dichotomization point for Kaplan Meier curves (B).  Legend: AUC=area under the curve; CI=confidence interval; 
Tumor%=percentage of tumor cells; Tumorarea=tumor cells area; Sizemax=size of the largest fragment; TF=number 
of fragments; HR=hazard ratio. 
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Abstract 
Assessment of tumor response after chemotherapy using FDG PET metrics is gaining 
acceptance. Several studies have suggested that the parameters metabolically active tumor 
volume (MTV) or total lesion glycolysis (TLG) are superior for measuring the tumor burden 
compared to the maximum standardized uptake value (SUVmax). However, the measurement 
of MTV and TLG is still controversial; the most commonly method uses an absolute threshold 
of 42% of SUVmax. Recently we implemented a background adaptive method to determine 
the background subtracted lesion activity (BSL) and the background subtracted volume (BSV). 
In this study, we investigated the correlation between such PET metrics and histopathological 
response in non-small cell lung carcinoma (NSCLC). 
Patients and Methods: Forty-four NSCLC patients were retrospectively identified. Their PET/CT 
data before and after neo-adjuvant chemotherapy was analyzed regarding SUVmax, MTV, TLG, 
BSL, and BSV on both scans and the relative changes (delta = d) were calculated (dSUVmax, 
dMTV, dTLG, dBSL, and dBSV). The tumor regression grade (TRG) as an indicator of 
histopathological response was assessed on H&E stained sections of the surgical specimens 
using a 4-tiered scale (TRG1–TRG4). The TRG was correlated with the absolute PET metrics 
after chemotherapy and their relative changes, respectively, using Spearman’s rank 
correlation tests. 
Results: Tumors that demonstrated a good response after neo-adjuvant chemotherapy had 
significantly lower FDG activity than non-responders (TRG3-4: SUVmax 4.2 (1.8-7.9) versus 
TRG1-2: SUVmax 8.1 (1.4- 40.4), p=0.001). The same was found for dSUVmax and TRG 
(p=0.001). PET volume metrics based on a 42% fixed threshold of SUVmax did not correlate 
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with TRG (TLG: p=0.505 and MTV: p=0.386). However, both background activity-based PET 
volume metrics BSL and BSV significantly correlated with TRG (p<0.001 each). 
Conclusion: PET volume metrics based on background adaptive methods correlate better with 
histopathological TRG in NSCLC patients under neo-adjuvant chemotherapy than 
algorithms/methods using a fixed threshold (42% SUVmax). 
 
Key words: Volume segmentation, tumor regression, quantification, NSCLC, neo-adjuvant 
therapy.
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Introduction 
Therapy response assessment is a fast increasing field for FDG PET/CT in oncology imaging 
(132). The correlation between the maximum standardized uptake value (SUVmax) and the 
histopathological tumor regression upon radiotherapy (133) or neo-adjuvant chemotherapy 
(120) has been established in non- small cell lung cancer (NSCLC) patients. However some 
limiting factors might result in false elevated SUVmax, such as increased macrophage 
infiltration, that result in false elevated SUVmax values (134) or false negative results might 
occur in large bulky lesions where residual vital tumor can be present, despite complete 
metabolic response according to the SUVmax (122). Nevertheless, a complete metabolic 
response in FDG PET is superior to CT volume assessment for evaluating histopathological 
response (125). De Geus-Oei et al analyzed the metabolic rate of glucose (MRGlu) as well as 
the SUV after induction chemotherapy and showed that a decrease in SUVmean of more than 
35% correlated best with a favorable progression free and overall survival (135). 
Recent publications focusing on FDG PET segmentation to assess total tumor burden, including 
metabolically active tumor volume (MTV) and total lesion glycolysis (TLG) showed superior 
correlation with progression free and overall survival of NSCLC compared to SUVmax (136-
139). In particular, a multivariate analysis identified TLG and treatment method (surgery vs. 
other) to be the only two independent prognostic factors for progression free survival (140). 
TLG and MTV were suggested by Larson et al in 1999 to determine total tumor burden and 
volume using PET data (141). With the combination of CT and PET images, volume 
measurement via PET became less central for NSCLC, since tumor volume can be easily 
assessed on CT. However, with an increasing number of publications suggesting that MTV and 
TLG are superior in assessing NSCLC response compared to SUVmax, the question how to 
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measure them is relevant again (142, 143). In most of the recent studies, MTV and TLG were 
computed using a fixed SUVmax threshold of 40- 50% (144-146). We have recently shown that 
this threshold method has limitations for the measurement of lesion activity and volume: MTV 
and TLG based on a fixed threshold using SUVmax (e.g. 42%) will underestimate lesion’s uptake 
with a high activity, and overestimate lesions with a SUVmax close to background (147). Other 
authors have used a fixed SUV threshold, most commonly SUV 2.5 (148-150), with the obvious 
limitations of an arbitrary cut off. Lesions with low activity are thereby underestimated or not 
even measurable. We have therefore developed a background based estimation method 
including background subtracted lesion activity (BSL), and background subtracted lesion 
volume (BSV) (Fig. 1). 
 
 
Figure 1:  Illustration of both segmentation methods. (A) Using an absolute threshold of SUVmax of 42% to delineate 
an ideal homogeneous sphere has been shown to optimally segment the true volume of the sphere (yellow). (B) 
For heterogeneous real tumors however, the 42% cut off would miss a substantial number of tumor voxels 
(yellow), while the subtraction of the Gaussian normal distribution representing the background (green) is 
including all voxels with activity above background, yielding the background subtracted tumor volume (BSV). 
 
Our method uses a single volume of interest (VOI) that surrounds the tumor and reads its 
histogram to measure the total activity within the lesion (147). It is based on our previously 
published study showing that background activity can be assessed automatically within the 
tumor VOI using histogram analysis (151). Since background voxels have more homogeneous 
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values, they will always represent the mode in a selected VOI, with a normal Gaussian 
distribution. Therefore, background voxels can be removed from the VOI by subtraction of a 
normal distribution fitted to the first peak in the histogram (147). 
In this study, we wanted to test the performance of the relative change of the FDG PET tumor 
volume metrics MTV, TLG, BSV, and BSL in non-small cell lung carcinoma treated with neo-
adjuvant chemotherapy. We chose the histopathological tumor regression grade (TRG), 
described by Juncker et al (105, 106) of the corresponding formalin-fixed and paraffin-
embedded surgical specimens as independent reference for tumor response. 
Materials and Methods 
 
Patient selection 
 
Patients with locally advanced stage II, stage III or oligometastatic stage IV disease underwent 
neo-adjuvant chemotherapy according to international guidelines following decision at our 
local tumor board (152). Patients must have received a FDG PET/CT scan before neoadjuvant 
treatment as well as before surgery between January 2002 and December 2012. This 
retrospective study was approved by the Ethical Commission of the Canton of Zurich and the 
requirement to obtain informed consent was waived. From a total of 92 NSCLC patients 
undergoing surgery after neo-adjuvant chemotherapy, 44 met all inclusion criteria. Most 
patients were diagnosed with stage III, at diagnosis. After neo-adjuvant treatment, only 3 
patients showed tumors with ypT0, while ypT3 predominated. Demographic details are given 
in Table 1. 
PET/CT acquisition and analysis 
 
Inclusion criteria for FDG PET/CT were the following: Scans of adequate quality, patients having 
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been fasting for at least 4 hours, blood glucose not elevated, FDG uptake time within 45-60 
minutes and FDG injection adequate (< 100 MBq difference between both FDG injections). All 
patients were examined using a routine clinical protocol in the Institute of Nuclear Medicine 
on dedicated PET/CT scanners (GE Healthcare DSTX, 16-or 64-slices CT, 7-8 frames, frame time 
1.5 or 2 minutes) with injection of 350 MBq FDG 45 - 60 minutes before examination. A low 
dose unenhanced CT-scan was performed for attenuation correction and used for anatomical 
localization (80 mA, 140 kV). Image analysis was performed by a dual board certified nuclear 
medicine physician and radiologist (IAB), who was blinded for the results of the histopathology. 
A volume of interest (VOI) was placed around the primary tumor, in a way that the entire 
tumor activity was within the VOI, while avoiding regions of physiologically increased activity 
(e.g. FDG-uptake of the heart). If high activity structures cannot be avoided, they have to be 
cut out, prior to the analysis. VOI placement instructions were previously published (23). In 
brief, VOI size had to be slightly bigger than the tumor. For lesions with heterogeneous 
background (e.g. tumors abutting lung and mediastinal tissue or hilar vessels) VOIs were 
adjusted to make sure that more of the background tissue with higher FDG activity was 
included (e.g. mediastinum). Within the selected VOI SUVmax and MTV and TLG as well as BSL 
and BSV were measured. The relative change (delta = d) in FDG PET metrics before and after 
neo-adjuvant chemotherapy was calculated (dSUVmax, dMTV, dTLG, dBSL and dBSV). On CT, 
the maximal tumor diameters were measured in three dimensions (a,b,c) and tumor volume 
was estimated as an ellipsoid using the formula: TVOL=4/3πx(a/2xb/2xc/2), with the 
corresponding relative change for CTVOL (dCTVOL) (153). 
 
Histopathological assessment of tumor regression 
 
For histopathologic assessment inclusion criteria were: presence of original H&E stains from 
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at least 2 representative whole tumor slides for regression scoring, no secondary simultaneous 
tumor, histologic subtype either adeno- or squamous cell carcinoma (other types were 
excluded). Only the primary tumors were analyzed. All H&E stains of the resection specimens 
manufactured for the original sign-out were entirely reviewed by RC and AS for assessment of 
the TRG. The TRG was scored on a 4- tiered scale based on the scoring system described by 
Junker et al (24, 25). This system evaluates the proportion of viable tumor cells in relation to 
the degree of tumor necrosis and fibrosis. In brief, TRG1 is defined as no or only minor, mostly 
spontaneous tumor regression. TRG2 shows more than 10% vital tumor tissue, whereas TRG3 
includes all tumors with less than 10% vital tumor epithelia. TRG4 is complete tumor regression 
whereby only fibrotic and necrotic areas with macrophage-rich xanthomatous inflammation 
remain in the original tumor volume. For dichotomized data analysis a score of TRG1-2 was 
regarded as low regression and therefore patients were considered as non-responders to 
treatment, while patients with TRG3-4 tumors were considered as responders. 
 
Statistical Analysis 
 
The distribution of the relative change for all PET metrics in the different histopathological 
tumor regression grades was analyzed using box plots. Correlations between TRG and the 
different absolute and relative PET metrics dSUVmax, dMTV, dTLG, dBSL and dBSV as well as 
dCTvol were calculated using Spearman’s rank tests. A receiver operator characteristic (ROC) 
curve was generated for SUVmax, after chemotherapy and dSUVmax, dMTV, dTLG, dBSL and 
dBSV for TRG responders versus non-responders. The area under the curve (AUC) was 
calculated. The optimal cut off point for the ROC curve was determined with the Youden index, 
calculated as the maximum of sensitivity + specificity–1, for each cut off value (154). 
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Table 1: Summary of patient demographics. FDG = Fluorodeoxyglucose, cT = clinical T-stage, ypT = pathology T-
stage after chemotherapy 
 
  N % 
Patients 44   
Age at surgery in years (median, range) 62 (38-75) 
Body weight in kg (median, range) 70 (43-123) 
FDG dose in MBq (median, range) 352 (274-430) 
Sex (male/female) 25/19 (56.8 / 43.2) 
Histology    
Squamous cell carcinoma 23 (52.3) 
Adenocarcinoma 21 (47.7) 
Clinical stage at diagnosis   
II 6 (13.6) 
III 35 (79.5) 
IV 3 (6.8) 
Tumor location   
Left lower lobe 6 (13.6) 
Left upper lobe 15 (34.1) 
Right lower lobe 6 (13.6) 
Right middle lobe 3 (6.8) 
Right upper lobe 14 (31.8) 
Pathological stage after chemotherapy  
0 3 (6.8) 
I 5 (11.4) 
II 10 (22.7) 
III 25 (56.8) 
IV 1 (2.3) 
CT(based cT at diagnosis   
cT1 3 (6.8) 
cT2 25 (56.8) 
cT3 9 (20.5) 
cT4 7 (15.9) 
ypT after chemotherapy   
ypT0 3 (6.8) 
ypT1 5 (11.4) 
ypT2 10 (22.7) 
ypT3 25 (56.8) 
ypT4 1 (2.3) 
Chemotherapy   
Cycles (median, range) 3 (2-6)  
Platinum/Gemcitabine 17 (51.6) 
Platinum/Taxane 25 (56.8) 
Others 3 (6.8) 
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Results 
In 13 patients the TRG was 3 or 4, these were thus considered as responders. Only 1 patient 
did not show any histologic regression (TRG1), while 30 patients had a TRG2 on histopathology. 
Lesions with good response to neo-adjuvant chemotherapy (TRG3-4) had a mean SUVmax of 
4.2 (range: 1.8-7.9), while lesions regarded as non-responders (TRG1-2) had a mean SUVmax 
of 8.1 (range: 1.4-40.4). A cut off at SUVmax <6.4 after neo-adjuvant chemotherapy yielded a 
sensitivity and specificity of 85% and 58%, respectively to predict good pathologic response. 
Differences between responders and non-responders were significant for dSUVmax (p=0.001) 
and dBSL and dBSV (p<0.001, respectively), while dTLG and dMTV were not significantly 
different between responders and non-responders (Table 2).  
 
Table 2: Absolute values for PET metrics after chemotherapy in non-responders versus responders. SUV = 
Standardized uptake value, TLG = Total lesion glycolysis, MTV = Metabolic active tumor volume, BSL = Background 
subtracted lesion activity, BSV = Background subtracted volume, TRG = Tumor regression grade. 
 
 
  
 
PET metrics after 
chemotherapy 
 
Non-responders (TRG1-2, N = 31) 
 
Mean Median Min Max 
 
Responders (TRG3-4, N = 13) 
 
Mean Median Min Max 
SUVmax 8.1 7.3 1.4 40.4 4.2 4.0 1.8 7.9 
TLG 59.3 38.7 6.8 229.9 41.1 45.0 9.8 76.4 
MTV 13.9 9.1 1.1 43.8 23.2 15.1 5.9 69.1 
BSL 82.2 32.3 0.2 344.6 22.4 9.5 1.1 76.6 
BSV 19.5 9.6 0.1 82.2 6.7 3.1 0.7 20.6 
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Using the Spearman rank test dSUVmax correlated with the TRG with p=0.001. PET volume 
metrics based on a fixed threshold of SUVmax did not correlate with TRG (dTLG: p=0.505 and 
dMTV: p=0.386). However, both background activity based PET volume metrics dBSL and dBSV 
significantly correlated with TRG (p<0.001 for both) (Fig. 2). 
 
Figure 2: Boxplot illustrating that there was no correlation between TRG and the relative difference in PET volume 
metrics based on a fixed threshold of 42% SUVmax. (A) dTLG and (B) dMTV, while the correlation between TRG 
and background based metrics was significant (C) dBSL and (D) dBSV. 
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ROC analysis showed the largest area under the curve for BSV (AUC=0.799), followed by BSL 
(AUC=0.777) and SUVmax (AUC=0.767), while TLG and MTV had an AUC=0.529 and 0.387, 
respectively (Fig. 3). 
 
Figure 3: Receiver operator characteristic curve. ROC curve was generated for dSUVmax, dMTV, dTLG, dBSL and 
dBSV and TRG1-2 versus TRG3-4. BSV has the largest area under the curve (AUC=0.799), with cut off at -88% 
yielding a sensitivity and specificity of 69% and 81%, respectively. SUVmax and BSL are not significantly inferior 
with AUC=0.767 and AUC=0.777, respectively. 
 
 A cut off at -68% for dSUVmax showed a sensitivity and specificity of 69% and 84%, 
respectively. For dBSV a cut off at -88% gave sensitivity and specificity of 69% and 81% and for 
dBSL - 90% yielded a sensitivity and specificity of 77% and 74%, respectively (Table 3). 
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Table 3: Receiver operator characteristic curve analysis, with corresponding cut offs as well as sensitivities and 
specificities. SUV = Standardized uptake value, dCTvol = relative difference in CT volume, dTLG = relative difference 
in total lesion glycolysis, dMTV = relative difference in metabolic active tumor volume, dBSL = relative difference 
in background subtracted lesion activity, dBSV = relative difference in background subtracted volume, CI = 
confidence interval. Na = not applicable.  
 
 
Figure 4 is illustrating a case of a stage IIIA central adenocarcinoma in the right hilum with high 
FDG-activity (SUVmax 16.1) prior to neo-adjuvant chemotherapy. After the chemotherapy a 
good partial metabolic response was achieved (SUVmax 4.9, -70%). However, MTV decreased 
only minimally form 22.2 to 18.4 cm3 (-17%) while BSV decreased substantially from 55.2 to 
2.4 cm3 (-96%). Histopathology showed extensive fibroelastotic scar tissue with small residual 
foci of vital adenocarcinoma growing in lepidic fashion along the alveolar walls, corresponding 
to TRG 3 (Fig. 5). 
  
PET metrics 
A  
Area Std. Error Sig. 95% CI Cut off Sensitivity Specificity 
SUVmax II 0.759 0.073 0.007 0.615-0.903 6.4 85% 58% 
dCTvol 0.677 0.097 0.066 0.488-0.867 -92% 54% 90% 
 
dSUVmax 
 
0.767 
 
0.086 
 
0.006 
 
0.598-0.936 
 
-68% 
 
69% 
 
81% 
 
dTLG 
 
0.529 
 
0.087 
 
0.767 
 
0.357-0.700 
 
na 
 
na 
 
na 
 
dMTV 
 
0.387 
 
0.092 
 
0.242 
 
0.206-0.568 
 
na 
 
na 
 
na 
 
dBSL 
 
0.777 
 
0.080 
 
0.004 
 
0.620-0.934 
 
-90% 
 
74% 
 
77% 
 
dBSV 
 
0.799 
 
0.069 
 
0.002 
 
0.663-0.935 
 
-88% 
 
69% 
 
84% 
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Figure 4: 52 year old woman, treated with cisplatin/pemetrexed based neo-adjuvant chemotherapy for a stage IIIA 
central adenocarcinoma in the right hilum (SUVmax 16.1). (A-C) Staging FDG PET/CT with (A) coronal MIP overview 
and (B-C) axial fused PET/CT with a tumor VOI around the lesion, illustrating that MTV gives a significantly lower 
volume compared to BSV in a lesion with high activity. (D-F) Restaging FDG PET/CT after 3 cycles of chemotherapy 
with a significant decrease in (SUVmax 4.9), correlating with a TRG3. While BSV decreased by 96%, MTV only 
decreased by 17% not entirely reflecting the good tumor response. 
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Figure 5:  Corresponding histologic whole section for the patient in figure 4 with a TRG3. (1) Extensive fibroelastotic 
scar tissue after neo-adjuvant chemotherapy (partial response) and normal, partially emphysematic lung (bottom 
left). (2) Central tumor part consisting of larger calcifications, heavy elastosis with complete vessel remodeling 
and enclosed anthracotic pigment. (3) Small residual focus of vital adenocarcinoma growing in lepidic fashion 
along the alveolar walls. Original magnifications 10x, H&E stains. 
 
Discussion 
Our results show that SUVmax after neo-adjuvant chemotherapy can distinguish “responders” 
from “non-responders”, with a high sensitivity of 85%, however with a rather low specificity of 
58%. The relative change in SUVmax (dSUVmax) is associated with tumor regression and a cut 
off at -68% predicts good to complete tumor regression with a specificity of 81% (TRG3-4). 
This is in line with previous studies, suggesting that a decrease in SUVmax is associated with 
good tumor response (155-157). One study investigated the relation between quantitative 
FDG metrics with pathologic tumor response and showed a linear relation between change in 
SUVmax and the percentage of nonviable tumor (124). They also came to the conclusion that 
metabolic parameters were superior compared to CT morphology for response assessment. 
This is in concordance with our results, showing that a decrease in dCTvol is yielding an AUC 
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of 0.677, compared to dSUVmax with 0.767 or dBSL with 0.799. 
An increasing number of studies are using SUV>2.5 as an absolute threshold (TLG2.5 or 
MTV2.5), especially for segmentation of lung tumors (148-150). In our cohort, one 
adenocarcinoma had an activity of SUVmax 2.4 before chemotherapy, which would not have 
been measurable with TLG2.5 or MTV2.5. 
Moreover, this adenocarcinoma decreased in BSL and BSV only by 50 and 60%, respectively, 
suggesting only partial metabolic response, which was confirmed by histopathology (TRG2). 
Furthermore, 8 lesions had a SUVmax<2.5 after chemotherapy, but only 4 were complete 
responders, of these 4 non-responding lesions, BSL and BSV suggested complete response only 
in one case. 
Previously published papers suggest that PET volume metrics such as MTV and TLG are 
superior to SUVmax for prediction of overall and progression free survival. However, MTV and 
TLG based on a fixed threshold (SUVmax 42%) failed to predict histopathological response in 
the current study, while the background adapted segmentation methods correlated with TRG. 
This might be explained with phantom results showing that a fixed threshold can lead to a 
substantial underestimation of TLG and MTV for lesions with high FDG uptake (147). A 
decrease of SUVmax under therapy therefore might lead to a false increase in MTV since a 
larger volume of less active tumor will be included into MTV. This is illustrated in Figure 4 with 
FDG PET/CT exams before and after neo-adjuvant chemotherapy, where MTV overestimates 
the volume after therapy, while BSV shows a good response. Histopathology confirmed tumor 
regression with TRG3 (Fig. 5). 
Also the original paper from Erdi et al, suggested that PET tumor segmentation requires an 
adapted threshold based on the tumor-to-background ratio (158). Drawing a separate VOI 
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over background for every lesion is time consuming especially in patients with multiple 
metastases. Therefore, we suggest our histogram based one-step method to measure tumor 
activity and to estimate the volume. For tumor volume definition before radiotherapy planning 
however, background based tumor segmentation has already been suggested previously with 
a separate VOI drawn over the background area by Nestle et al (159). Others further 
investigate histogram indices such as standard deviation, skewness, kurtosis, entropy and 
energy, however results are still controversial and those metrics were not part of the current 
study (160). 
In the present study, dSUVmax was not significantly inferior to dBSL and dBSV for prediction 
of tumor regression. This might reflect the importance of the most aggressive part within a 
tumor reflected by the highest SUV values, as compared to the metabolically active tumor 
volume. This will need further investigation in larger cohorts. 
The study has several limitations. The retrospective nature of the analysis leads to some 
inconsistencies in uptake time, and the injected FDG dose varied over time. Care was taken to 
exclude patients with high blood sugar, paravenous injection or scan artifacts (motion, metal 
implants). In addition, the chosen patient cohort represents a real patient population within 
the selected clinical setting and quantification measures should be reliable in such a setting, 
too. Also, we did not perform outcome analysis on the present patient population; we 
investigated the direct correlation between PET quantification and histopathology and believe 
that this patient population is too small and heterogeneous (stage, therapy, histology) to 
assess a meaningful correlation with progression free and overall survival. Therefore, follow 
up projects with larger homogeneous patient cohorts that underwent primary surgery without 
neo-adjuvant chemotherapy are planned. BSL and BSV are not intended to serve as a PET 
segmentation tool, since space information is lost in the histogram, and therefore selected 
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voxels do not have a one-to-one correspondence to the voxels in the images. BSV therefore 
may not provide an accurate segmentation of the tumor boundary, as is necessary for 
radiation therapy planning. The subtraction of background activity from the tumor VOI will 
represent the true BSL as the entire amount of activity coming from the tumor, irrespective of 
the location, i.e. it includes spill-out or spill-over. As a result, for delineation of tumor volume, 
a spill-over correction would be necessary and was not performed in this study, since we were 
interested in the relative change of the total activity/volume and not the boundary. The 
threshold at 42% of SUVmax suggested by Erdi can only be applied for homogeneous spheres 
with high lesion-to-background ratios (158). The heterogeneous nature of real tumors might 
be better reflected by the 15% of the average activity plus background, suggested by Nestle 
et al to delineate the tumor area for radiotherapy (159). For tumor burden assessment in 
oncology imaging the fact that spillover is regarded as a part of tumor volume might only 
weakly affect the accuracy of the overall assessment. This is suggested by the fact that BSV 
and BLS showed very similar correlation to TRG, while MTV and TLG did not. 
Conclusion 
The current data confirm that PET volume metrics based on a fixed threshold (42% SUVmax) 
lead to a significant bias and do not correlate with response to chemotherapy assessed on 
histopathology. PET volume metrics based on background-adapted measurements however, 
correlate with tumor regression. 
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Chapter 5 
Discussion and conclusions  
This doctoral thesis describes an image-based computational approach aiming at refining 
morphologic classification of lung squamous cell carcinoma. The presented study provides 
evidence that automatic image analysis can provide an accurate quantification of 
morphological parameters, potentially useful to build novel and prognostic classification 
systems. The field of pathology is facing dramatic changes since the popularisation and 
recognition of whole slide imaging (WSI) systems for the review of digital surgical pathology 
slides. The digitalization of whole tissue specimens has led to an incentive to develop automatic 
methods to support pathologic decision. Consequently, multitude of methods have been 
proposed to quantify morphological parameters in histopathological images (58, 161).  
Histologic revision of tissue sections is the essence of histopathologic disease classification. 
Since decades, pathologists have been using light microscopy to examine and extract 
meaningful parameters for the morphology of formalin-fixed tissue specimens or to evaluate 
the positivity of a given diagnostic marker (162). Because of this fixation method and the use 
of H&E and other chromogenic dyes, tissue specimens show extremely high longevity, which 
considerably facilitates retrospective studies. Among the popular dyes, diaminobenzidine (DAB) 
is a chromogenic IHC staining method resulting in a typical brown staining (163). Although 
practical for the above-mentioned reasons, this stain is not suitable for strictly quantitative 
intensity scoring, as most of the light is not emitted in contrast to immunofluorescence (164). 
Whereas most applications require a binary interpretation of the staining positivity, semi-
quantitative assessments might also be required with implications for treatment decision. 
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Hence, precise readouts are often required for accurate disease status reporting, despite the 
limitations of human judgment. In immunohistochemistry-based testing, pathologists have to 
deliberate whether a tumor is expressing a given threshold percentage of positivity. For 
example, breast cancers showing HER2 (Receptor tyrosine-protein kinase erbB-2) 
overexpression can be treated using anti-HER2 drugs such as Trazumab or Lapatinib (165). An 
IHC test using the following scale can be used to determine HER2 expression (166) : 0 
(negative), 1+ (also negative), 2+ (borderline), or 3+ (positive). However, this scoring method 
might be rather ambiguous (167) which would require fluorescence in situ hybridization (FISH) 
to confirm HER2-positivity (168, 169). Another representative pitfall can be shown for NSCLC, 
where the percentage of PD-L1 expressing tumor cells is a marker for immunotherapy efficacy. 
In the case of Pembrolizumab, patients with PD-L1 expression in at least 50% of tumor cells had 
a significantly better response to the treatment (44). However, drawing a line over a given score 
threshold cannot be humanly done without reliable quantitative tools other than subjective 
judgment or experience. For obvious reasons, the development of companion diagnostic tools 
to unify such quantitative measurements could have a significant impact on future clinical 
decisions. 
IHC evaluation is not only restricted to disease diagnostics but is also an important part of tissue 
biomarkers research (170). Biomarker studies often use semi-quantitative scales to evaluate 
the expression level of a given protein. In practice, the percentage of positive tumor cells, the 
intensity of the staining and an integrative H-score are commonly used to describe the 
expression level of a given biomarker (171). However, the manual evaluation of frequency or 
intensity levels is highly subjective and is prone to inter-observer variability (169). While the 
use of computerized methods does not seem to be a necessity to determine if a tumor is 
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immunoreactive for a given diagnostic marker, automatic evaluation of tissue samples can 
considerably decrease the time spent on routine tasks.  
Disease classification is another part of daily routine in pathology, whereby tumor stage is the 
best prognosticator and hence will decide upon disease treatment. For lung cancer, this system 
evaluates the extent of the disease by measuring the primary tumor and evaluating the 
presence the lymph node or distant metastasis (TNM staging) (21). Tumor size and location is 
the only determinant parameter for pathologic T (pT). However, in lung squamous cell 
carcinoma, it has been shown that histologic features can carry prognostic information (53-56). 
Therefore, another field of digital pathology is the discovery of prognostic markers able to 
stratify tumors into prognostic groups. A common approach relies on the extraction of cell or 
nuclear shape descriptors or features (161). This approach has shown to provide prognostic 
information for NSCLC (62, 63). However, accurate cell segmentation of H&E stained sections 
is complex and features extracted are highly dependent on the quality of image segmentation. 
Deep learning algorithms are increasingly popular for image classification as they allow 
unsupervised feature learning, which is particularly powerful for pattern recognition on 
histologic sections (172). Examples of histopathologic features detection using convolutional 
neural networks include cancer cell nuclei (173, 174), mitosis detection (175, 176), tumor 
grading  (177) and metastasis detection (64). 
In our study, we proposed an alternative approach to evaluate higher-level structures related 
to the overall tumor microarchitecture. A high contrast between tumor tissue and its 
surrounding stroma could be achieved using AE1/AE3 IHC, which is specific to epithelial cells. 
As shown previously, such an approach can reliably segment lung cancer tissue from its 
surrounding stroma (109, 178). Therefore, analyzing connected epithelial tumor elements 
rather than individual cells might reflect better the overall invasion pattern of solid carcinomas, 
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generally depicted as collective cell migration (82, 83). In chapter 2, we hypothesized that the 
amount of tumor clusters would be a marker of tumor invasiveness as several studies suggested 
that the presence of small clusters or buds are prognostic (budding and sheets). Nevertheless, 
these structures may represent two-dimensional projections of the 3D branching of the tumor 
(101). Instead of focusing on small clusters, we included an overall fragmentation 
independently of cluster size. The integration of molecular data showed that several biological 
processes, mostly related to extracellular matrix remodeling and cell invasion were 
upregulated, thus suggesting that the presence of high amount of fragments indicates tumor 
invasion. In this first study, we used an intuitive and understandable parameter to provide a 
basis grading scoring applicable in pathology. However, a more comprehensive analysis could 
be performed by extracting multiple shape descriptors. This data could further be used to 
estimate automatically the potential risk given the overall tumor morphology. This hypothesis 
would be ideally followed-up in further studies but would require a validation set to test such 
model.  
Although surgical resection is the most common procedure for intended curation, additional 
chemotherapy or radiotherapy treatment can be given in a neoadjuvant setting, in order to 
reduce the tumor burden before marginal resection of the tumor (152, 179). The radiologic 
evaluation post-treatment is an important step to guide further treatment. This is mainly 
achieved following response criteria (RECIST) which is a metric of radiologic response (180). 
The metabolic activity of the tumor measured by PET, as standardized uptake value is an 
imaging method especially helpful to detect metastases (17). However, these imaging methods 
are not specific enough, and would require histopathologic confirmation (19).  
On a daily practice, tumor size is an essential parameter for TNM staging. However, after 
neoadjuvant treatment, the measurement of residual tumor burden can be cumbersome as 
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microscopic tumor islands may remain. Several studies have proposed regression systems for 
NSCLC, based on the amount of residual tumor tissue (105, 107-109). Nevertheless, most 
studies rely on manual measurements or the remaining tumor burden on H&E stained tissue. 
In chapter 3, we have extended our computerized method to a patient cohort, having received 
neoadjuvant chemotherapy. Once again, we have used intuitive parameters related to the 
remaining tumor burden. We have demonstrated that the automatic scores were performing 
better than manual assessment of tumor regression, which highlights the significance of using 
automated methods to support pathologic diagnostic. In addition, we have shown in this 
Chapter 3 and 4 that not all PET measurements correlate with histologic tumor burden. 
Therefore, a careful selection of PET parameters should be done before trying to address the 
tumor response to treatment. 
In conclusion, in this doctoral thesis, we provided evidence that the use of image-based 
computational methods is a reliable approach to supervise pathologists for disease 
classification. We have proposed an approach for accurate quantification of morphological 
parameters of lung squamous cell carcinomas, which could provide a solid basis for building 
novel classification systems. 
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